<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1209234184
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LIXIANA 30 mg film coted tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        EDOXABAN TOSILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        240
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Daiichi Sankyo Europe GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Daiichi Sankyo Europe GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AF03 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lixiana contains the active substance edoxaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent blood clots from forming. It works by blocking the activity of factor Xa, which is an important component of blood clotting.</p><p>Lixiana is used in adults to:</p><p>- Prevent blood clots in the brain (stroke) and other blood vessels in the body if you have a form of irregular heart rhythm called nonvalvular atrial ﬁbrillation and at least one additional risk factor.</p><p>- Treat blood clots in the veins of the legs (deep vein thrombosis) and in the blood vessels in the lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels in the legs and/or lungs.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Lixiana:</strong></p><p>- If you are allergic to edoxaban or any of the other ingredients of this medicine.</p><p>- If you are actively bleeding</p><p>- If you have a disease or condition that increases the risk of serious bleeding (e.g. stomach ulcer, injury or bleeding in the brain, or recent surgery of the brain or eyes)</p><p>- If you are taking other medicines to prevent blood clotting (e.g. warfarin, dabigatran, rivaroxaban, apixaban or heparin), except when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open</p><p>- If you have a liver disease which leads to an increased risk of bleeding</p><p>- If you have uncontrolled high blood pressure</p><p>- If you are pregnant or breast-feeding</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Lixiana, - If you have an increased risk of bleeding, as could be the case if you have any of the following conditions:</p><p>&bull; end-stage kidney disease or if you are on dialysis</p><p>&bull; severe liver disease</p><p>&bull; bleeding disorders</p><p>&bull; a problem with the blood vessels in the back of your eyes (retinopathy)</p><p>&bull; recent bleeding in your brain (intracranial or intracerebral bleeding)</p><p>&bull; problems with the blood vessels in your brain or spinal column</p><p>-if you have a mechanical heart valve Lixiana 15 mg is only to be used when changing from Lixiana 30 mg to a vitamin K antagonist (e.g. warfarin) (see section 3. How to take Lixiana.)</p><p><strong>-If you need to have an operation</strong>: It is very important to take Lixiana before and after the operation exactly at the times you have been told by your doctor. If possible, Lixiana should be stopped at least 24 hours before an operation. Your doctor will determine when to restart Lixiana.</p><p><strong>Children and adolescents </strong></p><p>Lixiana is not recommended in children and adolescents under 18 years of age. There is no information on its use in children and adolescents.</p><p><strong>Other medicines and Lixiana </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p><strong>If you are taking any of the following:</strong></p><p>&nbsp;&bull; some medicines for fungal infections (e.g. ketoconazole)</p><p>&bull; medicines to treat abnormal heart beat (e.g. dronedarone, quinidine, verapamil)</p><p>&bull; other medicines to reduce blood clotting (e.g. heparin, clopidogrel or vitamin k antagonists such as warfarin, acenocoumarol, phenprocoumon or dabigatran, rivaroxaban, apixaban)</p><p>&bull; antibiotic medicines )e.g. erythromycin, clarithromycin(</p><p>&bull; medicines to prevent organ rejection after transplantation (e.g. ciclosporin)</p><p>&bull; anti-inﬂammatory and pain-relieving medicines (e.g. naproxen or acetylsalicylic acid (aspirin))</p><p>&nbsp;&bull; antidepressant medicines called selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors Tell your doctor before taking Lixiana, because these medicines may increase the eﬀects of Lixiana and the chance of unwanted bleeding. Your doctor will decide, if you should be treated with Lixiana and if you should be kept under observation.</p><p><strong>If you are taking any of the following:</strong></p><p>&bull; Some medicines for treatment of epilepsy (e.g. phenytoin, carbamazepine, phenobarbital)</p><p>&bull; St John&rsquo;s Wort, an herbal product used for anxiety and mild depression</p><p>&bull; Rifampicin, an antibiotic</p><p><strong>If any of the above apply to you, tell your doctor&nbsp;</strong>before taking Lixiana, because the eﬀect of Lixiana may be reduced. Your doctor will decide if you should be treated with Lixiana and if you should be kept under observation.</p><p><strong>&nbsp;Pregnancy and breast-feeding</strong></p><p>&nbsp;Do not take Lixiana if you are pregnant or breast-feeding. If there is a chance that you could become pregnant, use a reliable contraceptive while you are taking Lixiana. If you become pregnant while you are taking Lixiana, immediately tell your doctor, who will decide how you should be treated.</p><p><strong>Women of childbearing potential</strong><br />The risk of bleeding from the uterus, potentially requiring<br />interventions, known to take place with oral anticoagulants including<br />LIXIANA should be assessed in females of reproductive potential and<br />those with bleeding from the uterus that is longer than usual or that<br />occurs at an irregular time.<br />&nbsp;</p><p><strong>Driving and using machines </strong></p><p>Lixiana has no or negligible eﬀects on your ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>&nbsp;How much to take</strong> the recommended dose is one 60 mg tablet once daily.</p><p>- <strong>If you have impaired kidney function</strong>, the dose may be reduced to one 30 mg tablet once daily by your doctor.</p><p>- <strong>If your body weight is 60 kg or lower</strong>, the recommended dose is one 30 mg tablet once daily.</p><p>- <strong>If your doctor has prescribed medicines known as P-gp inhibitors</strong>: ciclosporin, dronedarone, erythromycin, or ketoconazole, the recommended dose is one 30 mg tablet once daily.</p><p><strong>How to take the tablet </strong></p><p>Swallow the tablet, preferably with water.</p><p>&nbsp;Lixiana can be taken with or without food.</p><p>If you have difficulty swallowing the tablet whole, talk to your doctor<br />about other ways to take Lixiana. The tablet may be crushed and<br />mixed with water or apple puree immediately before you take it. If<br />necessary, your doctor may also give you the crushed Lixiana tablet<br />through a stomach tube.<br />&nbsp;</p><p><strong>Your doctor may change your anticoagulant treatment as follows:</strong></p><p>&nbsp;Changing from vitamin K antagonists (e.g. warfarin) to Lixiana</p><p>Stop taking the vitamin K antagonist (e.g. warfarin). Your doctor will need to do blood measurements and will instruct you when to start taking Lixiana.</p><p>Changing from non-VKA oral anticoagulants (dabigatran, rivaroxaban, or apixaban) to Lixiana</p><p>Stop taking the previous medicines (e.g. dabigatran, rivaroxaban, or apixaban) and start Lixiana at the time of the next scheduled dose.</p><p>Changing from parenteral anticoagulants (e.g. heparin) to Lixiana Stop taking the anticoagulant (e.g. heparin) and start Lixiana at the time of the next scheduled anticoagulant dose.</p><p>Changing from Lixiana to vitamin K antagonists (e.g. warfarin)</p><p>If you currently take 60 mg Lixiana:</p><p>&nbsp;Your doctor will tell you to reduce your dose of Lixiana to a 30 mg tablet once daily and to take it together with a vitamin K antagonist (e.g. warfarin).</p><p>Your doctor will need to do blood measurements and will instruct you when to stop taking Lixiana.</p><p>If you currently take 30 mg (dose reduced) Lixiana:</p><p>Your doctor will tell you to reduce your dose of Lixiana to a 15 mg tablet once daily and to take it together with a vitamin K antagonist (e.g. warfarin). Your doctor will need to do blood measurements and will instruct you when to stop.</p><p>&nbsp;</p><p>taking Lixiana.</p><p>&nbsp;Changing from Lixiana to non-VKA oral anticoagulants (dabigatran, rivaroxaban, or apixaban)</p><p>&nbsp;Stop taking Lixiana and start the non-VKA anticoagulant (e.g. dabigatran, rivaroxaban, or apixaban) at the time of the next scheduled dose of Lixiana. Changing from Lixiana to parenteral anticoagulants (e.g. heparin) Stop taking Lixiana and start the parenteral anticoagulant (e.g. heparin) at the time of the next scheduled dose of Lixiana.</p><p><strong>If you take more Lixiana than you should </strong></p><p>Tell your doctor immediately if you have taken too many Lixiana tablets. If you take more Lixiana than recommended, you may have an increased risk of bleeding.</p><p><strong>If you forget to take Lixiana</strong></p><p>&nbsp;You should take the tablet immediately and then continue the following day with the once daily tablet as usual. Do not take a double dose on the same day to make up for a forgotten dose.</p><p><strong>If you stop taking Lixiana</strong></p><p>Do not stop taking Lixiana without talking to your doctor ﬁrst, because Lixiana treats and prevents serious conditions.</p><p>&nbsp;If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side eﬀects, although not everybody gets them.</p><p>Like other similar medicines (medicines to reduce blood clotting), Lixiana may cause bleeding which may potentially be life-threatening. In some cases, the bleeding may not be obvious.</p><p>&nbsp;If you experience any bleeding event that does not stop by itself or if you experience signs of excessive bleeding (exceptional weakness, tiredness, paleness, dizziness, headache or unexplained swelling) consult your doctor immediately.</p><p>Your doctor may decide to keep you under closer observation or change your medicine.</p><p><strong>Overall list of possible side e</strong><strong>ﬀects:</strong></p><p><strong>Common </strong>(may aﬀect up to 1 in 10 people):</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal liver blood tests</p><p>&bull; Bleeding from the skin or under the skin</p><p>&bull; Anaemia (low levels of red blood cells)</p><p>&bull; Bleeding from the nose</p><p>&bull; Bleeding from the vagina</p><p>&bull; Rash</p><p>&bull; Bleeding in the bowel</p><p>&bull; Bleeding from the mouth and/or throat</p><p>&bull; Blood found in your urine</p><p>&bull; Bleeding following an injury (puncture)</p><p>&bull; Bleeding in the stomach</p><p>&bull; Feeling sick</p><p>&bull; Itching</p><p><strong>Uncommon</strong> (may aﬀect up to 1 in 100 people):</p><p>&bull; Other types of bleeding</p><p>&bull; Bleeding in the eyes</p><p>&bull; Bleeding from a surgical wound following an operation</p><p>&bull; Blood in the spit when coughing</p><p>&bull; Bleeding in the brain</p><p>&bull; Allergic reaction</p><p>&bull; Hives</p><p><strong>Rare</strong> (may aﬀect up to 1 in 1,000 people):</p><p>●&nbsp;Bleeding in the muscles</p><p>&bull; Bleeding in joints</p><p>&bull; Bleeding in the abdomen</p><p>&bull; Bleeding in the heart</p><p>&bull; Bleeding inside the skull</p><p>&bull; Bleeding following a surgical procedure</p><p><strong>Not known )frequency cannot be estimated from the available</strong><br /><strong>data(:</strong><br />&bull; Bleeding in the kidney sometimes with presence of blood in urine<br />leading to inability of the kidneys to work properly )anticoagulantrelated nephropathy(.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg; C</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;Do not use this medicine after the expiry date which is stated on the carton and on each blister after EXP. The expiry date refers to the last day of that month. This medicine does not require any special storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- <strong>The active substance:</strong></p><p><strong>Lixiana 15 mg</strong>: Each ﬁlm-coated tablet contains <strong>15 mg edoxaban</strong> (as tosilate).</p><p><strong>Lixiana 30 mg</strong>: Each ﬁlm-coated tablet contains <strong>30 mg edoxaban</strong> (as tosilate).</p><p><strong>Lixiana 60 mg</strong>: Each ﬁlm-coated tablet contains <strong>60 mg edoxaban</strong> (as tosilate).</p><p><strong>- The other ingredients are:</strong></p><p>Lixiana 15 mg: mannitol, pregelatinised starch, crospovidone, hydroxypropylcellulose, magnesium stearate.</p><p>Lixiana 30 mg: mannitol, pregelatinised starch, crospovidone, hydroxypropylcellulose, magnesium stearate.</p><p>Lixiana 60 mg: Tablet core: mannitol, pregelatinised starch, crospovidone, hydroxypropylcellulose, magnesium stearate.</p><p>- <strong>Film coat:</strong></p><p>Lixiana 15 mg: hypromellose, macrogol 8000, titanium dioxide, talc, carnauba wax, iron oxide red, iron oxide yellow.</p><p>Lixiana 30 mg: hypromellose, macrogol 8000, titanium dioxide, talc, carnauba wax, iron oxide red.</p><p>Lixiana 60 mg: hypromellose, macrogol 8000, titanium dioxide, talc, carnauba wax, iron oxide yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lixiana 15mg: Orange, round-shaped ﬁlm-coated tablets (6.7 mm diameter) debossed with “SJ17E”. They come in blisters in cartons of 14 ﬁlm-coated tablets 
Lixiana 30mg: Pink, round-shaped ﬁlm-coated tablets (8.5 mm diameter) debossed with “SJ15E”. They come in blisters in cartons of 28 ﬁlm-coated tablets 
Lixiana 60mg: Yellow, round-shaped ﬁlm-coated tablets (10.5 mm diameter) debossed with “SJ13E”. They come in blisters in cartons of 28 ﬁlm-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SAJA Pharmaceuticals<br />Saudi Arabian Japanese pharmaceutical company limited<br />Jeddah &ndash; Kingdom of Saudi Arabia<br /><strong>Under license from</strong><br />Daiichi Sankyo company limited<br />Tokyo - Japan<br /><strong>For any information about this medicine, please contact</strong><br />Saudi Arabian Japanese pharmaceutical company limited<br />Jeddah &ndash; Saudi Arabia<br />P.O. Box: 42600, Jeddah 21551, KSA<br />Tel: + 966 12 606 6667<br />sajapharma.com<br />This leaflet was last revised in }September/2023{; version number }00{<br /><strong>-To report any side effect )s(</strong><br /><strong>&bull; Saudi Arabia</strong><br />- The National Pharmacovigilance Centre )NPC(:<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa<br /><strong>&bull; Other GCC States and other Countries:</strong><br />- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                September/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي ليكسيانا على المادة الفعالة إيدوكسابان وينتمي إلى مجموعة من الأدوية تدعى مضادات التجلط. يُساعد هذا الدواء على منع تكون الجلطات الدموية. يعما هذا الدواء بإحصار نشاط العامل العاشر أ، وهو عنصر مهم في عملية تخلط الدم.</p><p dir="RTL">يُستخدم ليكسيانا في البالغين للأغراض التالية:</p><p dir="RTL">⎯&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; منع تكون الجلطات الدموية في المخ (السكتة الدماغية) وفي الأوعية الدموية الأخرى بالجسم إذا كنت تعاني شكلًا من اضطرابات النظم القلبي يُدعى الرجفان الآديني أو إذا كان لديك عامل خطورة واحد على الأقل.</p><p dir="RTL">⎯&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج الجلطات الدموية في أوردة الساقين (الخثار الوريدي العميق) وفي الأوعية الدموية بالرئتين (انصمام رئوي)، ولمنع إعادة تكوين الجلطات الدموية في الأوعية الدموية في الساقين و/أو الرئتين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول ليكسانا في الحالات الآتية:</strong></p><p dir="RTL">⎯&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه إيدوكسابان أو أي مواد أخرى بهذا الدواء.</p><p dir="RTL">⎯&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تنزف بقوة.</p><p dir="RTL">⎯&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض أو حالة ترفع خطر الإصابة بنزيف خطير (على سبيل المثال: قرحة المعدة، أو إصابة أو نزيف بالمخ أو إذا كنت قد خضعت لجراحة مؤخرا بالمخ أو العينين).</p><p dir="RTL">⎯&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أذا كنت تتناول أدوية أخرى لمنع تخلط الدم (على سبيل المثال: وارفارين، أو دابيجاتران، أو ريفاروكسابان، أو أبيكسابان، أو هيبارين) ماعدا في حالة تغير العلاج المضاد للتجلط أو عند تلقي الهيبارين عبر أنبوب وريدي أو شرياني لإبقائه مفتوحًا (منع انسداده).</p><p dir="RTL">⎯&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني مرضًا كبديًا يؤدي إلى زيادة خطر الإصابة بنزيف.</p><p dir="RTL">⎯&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ضغط دم مرتفع وغير منضبط.</p><p dir="RTL">⎯&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حاملًا أو مرضعًا.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي الخاص بك قبل تناول ليكسيانا.</p><p dir="RTL">⎯&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تزايد خطر إصابتك بنزيف، كما قد يحدث إذا كنت تعاني من أي من الحالات التالية:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض كلوي في مرحلة الأخيرة أو إذا كنت تخضع لعلاج بالغسيل الكلوي.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض كبدي شديد.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات نزيف.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أحد مشاكل الأوعية الدموية في الجزء الخلفي من عينيك (اعتلال الشبكية).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصيبت مؤخرًا بنزيف في المخ (نزيف داخل الجمجمة أو داخل المخ).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالأوعية الدموية في المخ أو العمود الفقري.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديم صمام قلب اصطناعي.</p><p dir="RTL">لا يُستخدم ليكسيانا 15 ملج إلا عند الانتقال من استخدام ليكسيانا 30 ملج إلى أحد مضادات فيامين ك (على سبيل المثال: وارفاين) (انظر قسم: 3. كيفية تناول ليكسيانا)</p><p dir="RTL"><strong>إذا كنت تحتاج إلى الخضوع إلى عملية جراحية:</strong></p><p dir="RTL">من المهم جدًا تناول عقار ليكسيانا قبل العملية الجراحية وبعدها بالأوقات نفسها التي أخبرك بها الطبيب. إذا أمكن، يجب وقف تناول ليكسيانا قبل إجراء الجراحة ب 42 ساعة على الأقل. سيحدد طبيبك موعد إعادة بدء العلاج باليكسيانا.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُنصح بتناول ليكسيانا في الأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا. لا تتوفر معلومات حول استخدام ليكسيانا في الأطفال والمراهقين.</p><p dir="RTL"><strong>تناول ليكسيانا مع الأدوية الأخرى</strong></p><p dir="RTL">يُرجى إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أية أدوية أخرى.</p><p dir="RTL"><strong>إذا كنت تتناول أيا من الأدوية التالية:</strong><br />ُ - بعض الأدوية التي تستخدم لعلاج العدوى الفطرية (مثل: كيتوكونازول.)<br />- أدويــة تســتخدم لعلاج اضطــراب ضربــات القلــب (علــى ســبيل المثــال:<br />درونيــدارون، كينيديــن، فيراباميــل.)<br />َّ - أدويـة أخـرى للحـد مـن تجلـط الـدم (على سـبيل المثـال: هيباريـن، كلوبيدوجريل،<br />ِ أو مضــادات فيتاميــن ك مثــل: وارفاريــن، أسـينوكومارول، فينوبروكومــون، أو<br />دابيجاتـران، أو ريفاروكسـابان، أو أبيكسـابان.)<br />- الأدوية من المضادات الحيوية (مثل: الاريثروميسين، كلاريثروميسين.)<br />- أدويــة منــع رفــض الأعضــاء بعــد جراحــات زرع الأعضــاء (علــى ســبيل:<br />سيكلو ســبو ر ين ) .<br />- الأدويــة المضــادة للالتهابــات ومســكنات الألــم (مثــل: نابروكســين أو حمــض<br />أســيتيل الساليســيليك (الأســبرين.))<br />- الأدويـة المضـادة للاكتئـاب تسـمى مثبطـات امتصـاص السـيروتونين الانتقائيـة<br />أو مثبطـات امتصـاص السـيروتونين-نوربينيفرين.<br />ُ أخبــر طبيبــك بذلــك قبــل تنــاول ليكســيانا؛ لأن هــذه الأدويــة قــد تعــزز تأثيــرات<br />ليكســيانا وفرصــة الإصابــة بنزيــف غيــر مرغــوب بــه. ســيحدد طبيبــك مــا إذا كان<br />يجـب عاجـك بليكسـيانا، ومـا إذا كان يجـب أن تخضـع للمتابعـة المسـتمرة أم لا</p><p dir="RTL"><strong>إذا كنت تتناول أيًا من الأدوية التالية:</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أدوية علاج الصرع (على سبيل المثال: فينيتوين، كربامازييين، فينوباربيتال).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت حونز-منتج عشبي يُستخدم لعلاج القلق والاكتئاب الطفيف.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (مضاد حيوي)</p><p dir="RTL">إذا لك تكن متأكدًا مما إذا كان ينطبق عليك أي مما سبق، فأخبر طبيبك قبل تناول ليكسيانا، نظرًا لأن تأثير ليكسيانا قد يضعف. سيحدد طبيبك ما إذا كان يجب علاجك بليكسيانا، وما إذا كان يجب إبقاؤك تحت الملاحظة أم لا.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا تتناولي ليكسيانا إذا كنت حاملاً أو مُرضعًا. إذا كان من المحتمل أن تصبحي حاملًا، فاستخدمي وسيلة حمل موثق بها أثناء تناول ليكسيانا. إذا أصبحت حاملًا أثناء تناول ليكسيانا. فأخبري طبيبك على الفور وهو سيقرر كيفية علاجك.</p><p dir="RTL"><strong>النساء في سن الإنجاب</strong><br />يجــب تقييــم خطــر النزيــف مــن الرحــم، الــذي قــد يتطلــب تدخــلات جراحيــه،<br />والمعــروف أنــه يحــدث مــع مضــادات التخثــر الفمويــة بمــا فــي ذلــك ليكســيانا<br />فـي الإنـاث ذات القـدرة الإنجابيـة والنسـاء اللواتـي يعانيـن مـن نزيـف مـن الرحـم<br />أطــول مــن المعتــاد أو يحــدث فــي وقــت غيــر منتظــم</p><p dir="RTL"><br /><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">تأثير ليكسيانا على القيادة واستخدام الآلات منعدم أو لا يذكر</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدواء بالضبط كما أخبرك طبيبك أو الصيدلي الخاص بك. يُرجى مراجعة الطبيب أو الصيدلي إذا لم تكن متأكدًا من كيفية التناول.</p><p dir="RTL"><strong>ما الكمية التي يجب تتناولها؟</strong></p><p dir="RTL">الجرعة المُوصى بها هي قرص واحد 60 ملج مرة واحدة يوميًا.</p><p dir="RTL">-&nbsp;&nbsp; إذا كنت تعاني قصورًا بوظائف الكلى، فقد يخفض طبيبك جرعتك إلى قرص واحد 30 ملج مرة واحدة يوميًا.</p><p dir="RTL">-&nbsp;&nbsp; إذا كان وزنك 60 كجم أو أقل، فالجرعة الموصى بها هي قرص واحد 30 ملج مرة واحدة يوميًا.</p><p dir="RTL">-&nbsp;&nbsp; إذا وصف طبيبك لك أدوية تعرف باسم مثبطات البروتين السكري P-gp، مثل: سيكلوسبورين، أو درونيدارون، أو إريثروميسين، أو كيتوكونازول، فالجرعة الموصى بها هي قرص واحد 30 ملج مرة واحدة يوميًا.</p><p dir="RTL"><strong>كيفية تناول الأقراص</strong></p><p dir="RTL">ابتلع القرص، ويُفضل تناوله مع بعض الماء.</p><p dir="RTL">يمكن تناول ليكسيانا مع الطعام أو بدونه.</p><p dir="RTL">إذا كنـت تواجـه صعوبـة فـي ابتـلاع الأقـراص بالكامـل، فتحـدث إلـى الطبيـب<br />حـول وسـائل أخـرى لتنـاول ليكسـيانا. يمكـن طحـن الأقـراص وخلطهـا مـع المـاء<br />ً أو هريــس التفــاح فــورا ً قبــل تناولهــا. إذا لــزم الأمــر، قــد يقــوم الطبيــب أيضــا<br />بإعطائــك أقــراص ليكســيانا المطحونــة عبــر أنبــوب المعــدة<br />&nbsp;</p><p dir="RTL"><strong>قد يغير طبيبك علاجك المضاد للتخثر كما يلي:</strong></p><p dir="RTL">الانتقال من العلاج بمضادات فيتامين ك(على سبيل المثال: وارفادين) إلى ليكسيانا.</p><p dir="RTL">توقف عن تلقي العلاج بمضادات فيتامين ك(على سبيل المثال: وارفادين). سيحتاج طبيبك إلى إجراء قياسات للدم لك، وسيرشدك إلى وقت بدء علاج بليكسيانا.</p><p dir="RTL">الانتقال من العلاج بمضادات التجلط لغير فيتامين ك التي تعطى عن طريق الفم(دابيجاتران/أو ريفاروكسابان، أو أبيكسابان) إلى ليكسيانا.</p><p dir="RTL">توقف عن تناول الأدوية السابقة( على سبيل المثال: دابيجاترانو أو ريفاروكسابان، أو أبيكسابان) وابدأ تناول ليكسيانا في موعد الجرعة المقررة التالية.</p><p dir="RTL">الانتقال من مضادات التجلط التي تعطى عن طريق الحقن (على سبيل المثال: هيبارين) إلى ليكسيانا.</p><p dir="RTL">توقف عن تناول مضاد التجلط (على سبيل المثال: هيبارين)، وابدأ تناول ليكسيانا في موعد الجرعة المقررة التالية من مضادات التجلط.</p><p dir="RTL">الانتقال من العلاج بليكسيانا إلى مضادات فيتامين ك (على سبيل المثال: وارفادين).</p><p dir="RTL"><strong>إذا كنت تتناول حاليًا 60 ملج من ليكسيانا</strong>:</p><p dir="RTL">سيخبرك طبيبك بخفض جرعتك من ليكسيانا إلى قرص واحد 30 ملج مرة واحدة يوميًا، وتناوله مع مضاد فيتامين ك (على سبيل المثال: وارفادين). سيحتاج طبيبك إلى إجراء قياسات للدم لك، وسيرشدك إلى وقت وقف العلاج بليكسيانا.</p><p dir="RTL"><strong>إذا كنت تتناول حاليًا 30 ملج( حرعة مخفضة) من ليكسيانا:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">سيخبرك طبيبك بخفض جرعتك من ليكسيانا إلى قرص واحد 15 ملج مرة واحدة يوميًا، وتناوله مع مضاد فيتامين ك (على سبيل المثال: وارفادين). سيحتاج طبيبك إلى إجراء قياسات للدم لك، وسيرشدك إلى وقت وقف العلاج بليكسيانا.</p><p dir="RTL">الانتقال من العلاج بليكسيانا إلى مضادات التجلط لغير فيتامين ك عن طريق الفم (دابيجاتران، أو ريفاروكسابان أو أبيكسابان).</p><p dir="RTL">توقف عن تناول ليكسيانا وابدأ العلاج بمضادات التجلط لغير فيتامين ك ( على سبيل المثال: دابيجاتران، أو ريفاروكسابان أو أبيكسابان) في موعد الجرعة المقررة التالية من ليكسيانا.</p><p dir="RTL">الانتقال من العلاج بليكسيانا وابدأ العلاج بمضادات التجلط التي تعطي عن طريق الحقن (على سبيل المثال: هيبارين).</p><p dir="RTL">توقف عن تناول ليكسيانا وابدأ العلاج بمضادات التجلط لغير فيتامين ك التي تعطى عن طريق الحقن (على سبيل المثال: هيبارين) في موعد الجرعة المقررة التالية من ليكسيانا.</p><p dir="RTL"><strong>إذا تناولت كمية أكثر مما يجب من ليكسيانا</strong></p><p dir="RTL">أخبر طبيبك فورًا إذا تناولت كمية مفرطة من أقراص ليكسيانا.</p><p dir="RTL">أذا تناولت كمية أكثرمن الجرعة الموصى بها من ليكسيانا، فقد يؤدي ذلك إلى زيادة خطر تعرضك للنزيف.</p><p dir="RTL"><strong>إذا أغقلت تناول ليكسيانا</strong></p><p dir="RTL">يجب عليك تناول القرص الذي أغفلته فورًا، ثم تابع اليوم التالي تناول قرص واحد مرة يوميًا كالمعتاد، لا تتناول جرعة مضاعفة باليوم نفسه لتعويض جرعة أغفلتها.</p><p dir="RTL"><strong>إذا توقفت عن تناول ليكسيانا</strong></p><p dir="RTL">لا تتوقف عن تناول ليكسيانا بدون التحدث إلى طبيبك أولًا: نظرًا لأن ليكسيانا يعالج حالات خطيرة ويمنع حدوثها.</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدواء، فأستشر الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع</p><p dir="RTL">مثله مثل الأدوية المماثلة) الأدوية المستخدمة لخفض تجلط الدم)، قد يسبب ليكسيانا نزيفًا قد يهدد الحياة، في بعض الحالات، قد يكون النزيف غير ظاهر</p><p dir="RTL">أذا تعرضت لآية أحداث نزفية لا تتوقف من تلقاء نفسها، أو إذا كنت تعاني من علامات نزيف مفرط (أعراض غير معتادة من الضعف، التعب، الشحوب، الدوخة، الصداع، أو ورم غير معروف الأسباب)، فاستشر طبيبك فورًا</p><p dir="RTL">قد يقرر طبيبك إبقاءك تحت الملاحظة أكر دقة أو قد يقرر تغير دوائك</p><p dir="RTL">القائمة الكلية للآثار الجانبية المحتملة:</p><p dir="RTL"><strong>شائعة: (قد يؤثر على ما يصل إلى شخص واحد من بين كل أشخاص):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية باختبارات وظائف الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من الجلد أو تحت الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقرالدم (انخفاض مستويات خلايا الدم الحمراء).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من الانف.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من المهبل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في الامعاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من الفم /أو الحلق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دم في البول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف بعد الإصابة (وخز).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في المعدة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالإعياء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غير شائعة( قد تؤثر فيما يصل إلى شخص واحد من بين كل 100 شخص):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أنواع أخرى من النزيف.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في العينين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من جرح ناجم عن الجراحة بعد إجرائها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود دمفي البصاق عند السعال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في المخ.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شري.</p><p dir="RTL"><strong>نادرة( قد تؤثر فيما يصل إلى شخص واحد من بين كل 100 شخص):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في العضلات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في المفاصل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في البطن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف داخل الجمجمة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف بعد الجراحة.</p><p dir="RTL"><strong>غير معروف (لا يمكن تقدير معدل تكراره من خلال البيانات المتاحة:)</strong><br />ً &bull; نزيــف فــي الكلــى أحيانــا مــع وجــود دم فــي البــول ممــا يــؤدي إلــى عــدم<br />قــدرة الكلــى علــى العمــل بشــكل صحيــح (اعتــال الكليــة المرتبــط بمضــادات<br />التخثــر.)<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">يُحفظ هذا الدواء بعيدًا عن رؤية ومتناول الأطفال.</p><p dir="RTL">لاتستعمل هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة وعلى كل شريط بعد كلمة &ldquo;&Epsilon;&Chi;P&rdquo;. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">هذا الدواء لايحتاج لظروف تخزين خاصة.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق إلقائها في مياة الصرف أو من المخلفات المنزلية، استشر الصيدلي الخاص بك حول كيفيةالتخلص من الأدوية التي لم تعد تستخدمها. سوف تُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة:</p><p dir="RTL">ليكسيانا 15 ملج، يحتوي كل قرص مغلف على 15 ملج إيدوكسابان (في هيئة توسيلات).</p><p dir="RTL">ليكسيانا 30 ملج، يحتوي كل قرص مغلف على 30 ملج إيدوكسابان (في هيئة توسيلات).</p><p dir="RTL">ليكسيانا 60 ملج، يحتوي كل قرص مغلف على 60 ملج إيدوكسابان (في هيئة توسيلات).</p><p dir="RTL">المكوناتالأخرى:</p><p dir="RTL">ليكسيانا 15 ملج: مانيتول، كروسيوفيدون، نشا بريجيلاتينايزد، هيدروكسي بروبيل السليلوز، ستيرات الماغنسيوم.</p><p dir="RTL">ليكسيانا 30 ملج: مانيتول، كروسيوفيدون، نشا بريجيلاتينايزد، هيدروكسي بروبيل السليلوز، ستيرات الماغنسيوم.</p><p dir="RTL">ليكسيانا 60 ملج: مانيتول، كروسيوفيدون، نشا بريجيلاتينايزد، هيدروكسي بروبيل السليلوز، ستيرات الماغنسيوم.</p><p dir="RTL">الكسوة الغشائية:</p><p dir="RTL">ليكسيانا 15 ملج: هيبروميللوز، ماكروجول 800، ثاني أكسيد التابتانيوم، تلك، شمع كارنويا، أكسيد حديد أحمر، أكسيد حديد أصفر.</p><p dir="RTL">ليكسيانا 30 ملج: هيبروميللوز، ماكروجول 800، ثاني أكسيد التابتانيوم، تلك، شمع كارنويا، أكسيد حديد أحمر.</p><p dir="RTL">ليكسيانا 60 ملج: هيبروميللوز، ماكروجول 800، ثاني أكسيد التابتانيوم، تلك، شمع كارنويا، أكسيد حديد أصفر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ليكسيانا 15 ملج: أقراص برتقالية، مستديرة مغلفة(قطرها 6,7 مللي متر) محفور عليها&rdquo; SJ17E&rdquo; يتوفر في أشرطة في عبوات بها 14 قرصًا مغلفًا.</p><p dir="RTL">ليكسيانا 30 ملج: أقراص وردية، مستديرة مغلفة(قطرها 8,5 مللي متر) محفور عليها&rdquo; SJ15E&rdquo; يتوفر في أشرطة في عبوات بها 28 قرصًا مغلفًا.</p><p dir="RTL">ليكسيانا 60 ملج: أقراص صفراء، مستديرة مغلفة(قطرها 10.5 مللي متر) محفور عليها&rdquo; SJ13E&rdquo; يتوفر في أشرطة في عبوات بها 28 قرصًا مغلفًا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ساجا الصيدلانية<br />الشركة العربية السعودية اليابانية للمنتجات الصيدلانية المحدودة<br />جدة - المملكة العربية السعودية<br /><strong>بموجب ترخيص من</strong><br />شركة دايتشي سانكيو المحدودة، طوكيو - اليابان<br /><strong>للحصول على أي معلومات حول هذا الدواء، يرجى الاتصال بـ:</strong><br />الشركة العربية السعودية اليابانية للمنتجات الصيدلانية المحدودة<br />جدة , المملكة العربية السعودية<br />صندوق بريد ٤26٠٠جدة 21551المملكة العربية السعودية<br />+966126٠66667 :هاتف<br />sajapharma.com<br />تمت آخر مراجعة لهذه النشرة في {سبتمبر/ }2٠23؛ الإصدار رقم {}٠٠<br /><strong>-للإبلاغ عن أية آثار جانبية</strong><br /><strong>&bull; المملكة العربية السعودية</strong><br />- المركز الوطني للتيقظ والسامة الدوائية<br />- مركز اتصالات الهيئة العامة للغذاء والدواء السعودية : 19999<br />npc.drug@sfda.gov.sa :- البريد الإلكتروني<br />https://ade.sfda.gov.sa :- الموقع الإلكتروني<br /><strong>&bull; دول الخليج الأخرى/ الدول الأخرى</strong><br />- الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر/2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lixiana 30 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 30 mg edoxaban (as tosilate). For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.

Pink, round-shaped film-coated tablets (8.5 mm diameter) debossed with “SJ15E”.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age &ge; 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).</p><p>&nbsp;</p><p>Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p><em>Prevention of stroke and systemic embolism</em></p><p><em>&nbsp;</em></p><p>The recommended dose is 60 mg edoxaban once daily.</p><p>&nbsp;</p><p>Therapy with edoxaban in NVAF patients should be continued long term.</p><p>&nbsp;</p><p><em>Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTE)</em></p><p><em>&nbsp;</em></p><p>The recommended dose is 60 mg edoxaban once daily following initial use of parenteral anticoagulant for at least 5 days (see section 5.1). Edoxaban and initial parenteral anticoagulant should not be administered simultaneously.</p><p>&nbsp;</p><p>The duration of therapy for treatment of DVT and PE (venous thromboembolism, VTE), and prevention of recurrent VTE should be individualised after careful assessment of the treatment benefit against the risk for</p><p>&nbsp;</p><p>bleeding (see section 4.4). Short duration of therapy (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation) and longer durations should be based on permanent risk factors or idiopathic DVT or PE.</p><p>&nbsp;</p><p>For NVAF and VTE the recommended dose is 30 mg edoxaban once daily in patients with one or more of the following clinical factors:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; Moderate or severe renal impairment (creatinine clearance (CrCL) 15 - 50 mL/min)</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; Low body weight &le; 60 kg</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; Concomitant use of the following P-glycoprotein (P-gp) inhibitors: ciclosporin, dronedarone, erythromycin, or ketoconazole.</p><p>&nbsp;</p><p>Table 1: Summary of posology in NVAF and VTE (DVT and PE)</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Summary Guide for Dosing</strong></p></td></tr><tr><td style="vertical-align:top"><p>Recommended dose</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>60 mg once daily</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Dose recommendation for patients with one or more of the following clinical factors:</p></td></tr><tr><td style="vertical-align:top"><p>Renal Impairment</p></td><td style="vertical-align:top"><p><em>Moderate or severe (CrCL 15 &ndash;</em></p><p><em>50 mL/min)</em></p></td><td rowspan="3" style="vertical-align:top"><p>30 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>Low Body Weight</p></td><td style="vertical-align:top"><p>&le; <em>60 kg</em></p></td></tr><tr><td style="vertical-align:top"><p>P-gp Inhibitors</p></td><td style="vertical-align:top"><p><em>Ciclosporin, dronedarone, erythromycin, ketoconazole</em></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em>Missed dose</em></p><p><em>&nbsp;</em></p><p>If a dose of Lixiana is missed, the dose should be taken immediately and then be continued the following day with the once-daily intake as recommended. The patient should not take double the prescribed dose on the same day to make up for a missed dose.</p><p>&nbsp;</p><p><em><u>Switching to and from Lixiana</u></em></p><p><em>&nbsp;</em></p><p>Continued anticoagulant therapy is important in patients with NVAF and VTE. There may be situations that warrant a change in anticoagulation therapy (Table 2).</p><p>&nbsp;</p><p>Table 2: Switching</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Switching to Lixiana</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>From</strong></p></td><td style="vertical-align:top"><p><strong>To</strong></p></td><td style="vertical-align:top"><p><strong>Recommendation</strong></p></td></tr><tr><td style="vertical-align:top"><p>Vitamin K Antagonist (VKA)</p></td><td style="vertical-align:top"><p>Lixiana</p></td><td style="vertical-align:top"><p>Discontinue the VKA and start Lixiana when the international normalised ratio (INR) is &le; 2.5.</p></td></tr><tr><td style="vertical-align:top"><p>Oral anticoagulants other than VKA</p><p><strong>&nbsp;</strong></p><p>&bull;&nbsp;&nbsp; dabigatran</p><p><strong>&nbsp;</strong></p><p>&bull;&nbsp;&nbsp; rivaroxaban</p><p><strong>&nbsp;</strong></p><p>&bull;&nbsp;&nbsp; apixaban</p></td><td style="vertical-align:top"><p>Lixiana</p></td><td style="vertical-align:top"><p>Discontinue dabigatran, rivaroxaban or apixaban and start Lixiana at the time of the next dose of the oral anticoagulant (see section 5.1).</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Parenteral anticoagulants</p></td><td rowspan="2" style="vertical-align:top"><p>Lixiana</p></td><td style="vertical-align:top"><p>These medicinal products should not be administered simultaneously.</p><p><strong>&nbsp;</strong></p><p>Subcutaneous anticoagulant (i.e.: LMWH, fondaparinux):</p><p><strong>&nbsp;</strong></p><p>Discontinue subcutaneous anticoagulant and start Lixiana at the time of the next scheduled subcutaneous anticoagulant dose.</p></td></tr><tr><td style="vertical-align:top"><p>Intravenous unfractionated heparin (UFH):</p><p><strong>&nbsp;</strong></p><p>Discontinue the infusion and start Lixiana 4 hours later.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Switching from Lixiana</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>From</strong></p></td><td style="vertical-align:top"><p><strong>To</strong></p></td><td style="vertical-align:top"><p><strong>Recommendation</strong></p></td></tr><tr><td style="vertical-align:top"><p>Lixiana</p></td><td style="vertical-align:top"><p>Vitamin K Antagonist (VKA)</p></td><td style="vertical-align:top"><p>There is a potential for inadequate anticoagulation during the transition from Lixiana to VKA. Continuous adequate anticoagulation should be ensured during any transition to an alternate anticoagulant.</p><p><strong>&nbsp;</strong></p><p><em>Oral option: </em>For patients currently on a 60 mg dose, administer a Lixiana dose of 30 mg once daily together with an appropriate VKA dose.</p><p><strong>&nbsp;</strong></p><p>For patients currently on a 30 mg dose (for one or more of the following clinical factors: moderate to severe renal impairment (CrCL 15 &ndash; 50 mL/min), low body weight, or use with certain P-gp inhibitors), administer a Lixiana dose of 15 mg once daily together with an appropriate VKA</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>dose.</p><p><strong>&nbsp;</strong></p><p>Patients should not take a loading dose of VKA in order to promptly achieve a stable INR between 2 and 3. It is recommended to take into account the maintenance dose of VKA and if the patient was previously taking a VKA or to use valid INR driven VKA treatment algorithm, in accordance with local practice.</p><p><strong>&nbsp;</strong></p><p>Once an INR &ge; 2.0 is achieved, Lixiana should be discontinued. Most patients (85%) should be able to achieve an INR &ge; 2.0 within 14 days of concomitant administration of Lixiana and VKA. After 14 days it is recommended that Lixiana is discontinued and the VKA continued to be titrated to achieve an INR between 2 and 3.</p><p><strong>&nbsp;</strong></p><p>It is recommended that during the first 14 days of concomitant therapy the INR is measured at least 3 times just prior to taking the daily dose of Lixiana to minimise the influence of Lixiana on INR measurements. Concomitant Lixiana and VKA can increase the INR post Lixiana dose by up to 46%.</p></td></tr><tr><td style="vertical-align:top"><p><em>Parenteral option: </em>Discontinue Lixiana and administer a parenteral anticoagulant and VKA at the time of the next scheduled Lixiana dose. Once a stable INR of &ge; 2.0 is achieved, the parenteral anticoagulant should be discontinued and the VKA continued.</p></td></tr><tr><td style="vertical-align:top"><p>Lixiana</p></td><td style="vertical-align:top"><p>Oral anticoagulants other than VKA</p></td><td style="vertical-align:top"><p>Discontinue Lixiana and start the non-VKA anticoagulant at the time of the next scheduled dose of Lixiana.</p></td></tr><tr><td style="vertical-align:top"><p>Lixiana</p></td><td style="vertical-align:top"><p>Parenteral anticoagulant s</p></td><td style="vertical-align:top"><p>These agents should not be administered simultaneously. Discontinue Lixiana and start the parenteral anticoagulant at the time of the next scheduled dose of Lixiana.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em><u>Special populations</u></em></p><p><em>&nbsp;</em></p><p><em>Assessment of renal function:</em></p><p><em>&nbsp;</em></p><p>&bull;&nbsp;&nbsp; Renal function should be assessed in all patients by calculating the creatinine clearance (CrCL) prior to initiation of treatment with Lixiana to exclude patients with end stage renal disease (i.e. CrCL &lt; 15 mL/min),to use the correct Lixiana dose in patients with CrCL 15 &ndash; 50 mL/min (30 mg once daily), in patients with CrCL&gt; 50 mL/min (60 mg once daily) and when deciding on the use of Lixiana in patients with increased creatinine clearance (see section 4.4).</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; Renal function should also be assessed when a change in renal function is suspected during treatment(e.g. hypovolaemia, dehydration, and in case of concomitant use of certain medicinal products).</p><p>&nbsp;</p><p>The method used to estimate renal function (CrCL in mL/min) during the clinical development of Lixiana was the Cockcroft-Gault method. The formula is as follows:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; For creatinine in &micro;mol/L:</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="image2.png" o:spid="_x0000_s1027" type="#_x0000_t75"
  style='position:absolute;margin-left:36.7pt;margin-top:8.85pt;width:274.7pt;
  height:24pt;z-index:251658240;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAW4AAAAhCAYAAAD520GCAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsQAAA7EAZUrDhsAAAnFSURBVHhe7Z3dleI6DID3YaqinvRDPymFUnjhRrLlyLJkyyEMMFffOTm7cWRb/8kwDPwj7vfb43r5efxcro/b/f7Iwyr3+/pYfjbZfCxrLT+6fiZpr+WxZp29dtzXRZW5XS+/ovcR1mX36Q+z+Z1wf/38XB7X2/2xLunfLPLx3G/Xx2Ui3rPyFk08n1xXi0W+ZCLr5yizdVPZvqyNPPm4JwP0YsH3uFxvpk5euTOZySGznqpGO2p42Bj3QFPASAGZCOn6a5pMMn43ymtHkRMy2MyzriRztIheASbYID7vIvkuxYJunr9VBM8yU0S8oTybGzyeZ67LY5GHVGT9HGW2bmQe47lozOvi6xlW7KDvUP71epBX7kxmYz2sJ1R80Bju67UKdHnCzY6/3251M8RAPp8ckt66IzsgKa5ChuzgjrSeyt/FtzRuPFf8+VfwNCcozuvAdhnPsx4WPI37rLqcrRutCUl58N3yxE3fm3vvzNHZWHd19TRuDe2OSeDdxbgGwFypDAayMwfgd0pJzw5YG/aTMukuWCeyNvZOvqlxA70ClhzNg3cwKrqUN+OifGfj1urnSAxm64YaELdb6oJ+2fxw9KcPrx/P8vcRjuxt1lOv4Vn07gQYQMd6ECgKHOowKNaR0ZYdOC+vLWVSstc/Jnmcy5NM7kkFXK7jUSd0NX9gN8rmPUoB5LmV/2CM6WLtoenOdV5W2iP5payNh/CV0ixmkxP08eRBbTvs2fqCy1hNgdanMa5nL3bcrrJeiUu6ts+xf/TGuSxO0l9cV7LBk1Ojxt2LC+zpiQFxpG6KDdvaKMt8wElrJ7k81CBjV+aUQ/fDSI77HvUsfgc5lm9oAzsXtlTrdGJNyH3zMGL6VTYzD2iQMqdX5Bokz4vMIjnRTkzLDv66mZQ5noBJDwpsSSAxN9lXrw9BsuQ1MKjCLhxjAcYkWnYZaw+P7pTM65oTl+0tX4NM/qtjQgntiSnhzQPSkcuBrfwcdWa+MX0hfC/PZex2/+T5g9hbyHg2emw+rewZ6EVoseDw2OehCm8MgCN1A6R54MNWf85oLe26Z3/AkhvlCfmW4i7Py1zmZ0+OWPvixQ2znjBgSsPrMXoHgTcJMIk3ud7dldCShaPZAY7jrzlKGTUBhbN7SEfzoKnnJQnE0bFfFjrQrLvZQb727tHoriVN9oWlX/JfmwuosyOmxEweyBimXNtjeLsuLn839jtjZ/lL85+GjOc+Lz/ByTgN9CKsWBCj+nm2FilXLPtTA4I5yd6eLgDG1dBF87XX/725rjwZnHO8c7V94Tqh1pPW8HqAvKYkx/PUBcoUAyARBgkzSjzNjpKMygF7a0XAx9KebF7WUTp8D0Rtt9TZKroestAJPs6fhEd72LrXSUVwH8h4pmvtXmqiGUznAdMT/n/ddII1QDe8xub3fCHtHcauke+fW8h40rzk41bXkV6EFQvCmgdMx2BQN3mogmKUTxs/SHp6aL72+l+dO5Un/XOAxkY1NvIZgb6Svphp3OBMWbwWPBkk2rVRwoyM9NghZagouC6jdbgeatDwOgWt1peuWX7RsBK8rHWtfxvf26Onu2YLB/WQ9mAzEGOOmzZxJA8AitG62Q6NKOkB7xran7aBri9mYzfw18h/hIwnn0d2NE25oxehxYLDY5+HkEO1OFk3qq9xTL+RALCe5Ut7vdYWiTp3Ik+G58zPPtn9XMOsJ6sxSLRg8h9LOaiQY80ZpNESjx1acqFdeWy0B4Br5ITTA2MnI4B6sgKCOfDUiBcVenbJtQhrj7HudYJgHHPM0/V6L61ZyHVfASU86UrJrTUbyxe6/XbsdHmuw34O+llvC5TxlOumGNX6ev5YZti4xT7PMlM3JT7cbjYfhRij/qHtRzkxss+Sm8sT+9xTY3xva1+8uNHMoQF6nK8n145OynDZfFDgMGnacdzoRFAPUZw9OyQ4X9GN28edqlHvd9kSLP9/06v4rVynYy+8VqZflLLQOaiL0qysPUzdL9v/y/h2ULPOSU7j8q6vNu5OQZ6J/D0LxFCLne6LOmdgXjd2lR+2fVfdL6kIt6NjP49n7d9kT1VrKDfOKUCLhUSrn2ew6qb4kvmh8S+/JvKs5z9Z7xg72X+MmurJjfNExr3Ng5RHRo0tS6V389BRrilx7fjjK0hO6SfnO8EgsHd3ABRIral46DVu6yee30I2C0rCo7a+k1fETqMXTw2vXp7G/en1E9R8cz01pLvzZyafdndMTyX6E4AHq9CxCE98ejoCbxaUZPKp/Ft4Rew0phu3Uy9P4wY+uX6CHbWe9sfyOOKII444vuHI7TsIgiAIgiAIgiAIgiAIgiAIgiAIgiAI/sfQH2R43786K38UfCtf+S3/uW8T9NKzNb0lkOto68n/eMbzNsIgCIIuH924J96DfTZkJzRbzVb6sLEZf3jf/x0EQVABjWb0lV+fwLsbN2D9NSf/g6xo3EEQvJTfelo+g49u3FsDprFo3EFwMvVri/Xrj9VrqNvTExVg+tE4/QnsPjcVJhVyOS9zoBjZHFgv/xktnjsbUPO6rqrTboe0ARfZqMbz3lz3dKR1SFazr6zD9J+VJyqdHB8fgPJiHYwnG+ON8GgsqmtCN6txw0fcFh2icQfBeWBBVQ2nbnhUaLw490aUigu/UkwUr3WuN5D9fFTY2Khy06A14bMTNJ1IXrUB99P3lroDcmzfj69nrzGSByxd8aLBbOPG86KLPxawz/7pcXm+iAOXh7Hqo0CVNS2icQfBgFK04uluL25x4JOZXqh87NlzjaSrXtDafBrTbMgiiEeXkcxZ5yNdJc80brduit+rp3ghD9zXay0fjTsIziUVSmoU5anqYJM0i3/yXCPpWb+UQ2jzezYANIds7+ky0vfp84GuFr/SuJVGyvVt59/aj32Nxh0ErwGbABVjp9BkoQLTzWBwrtFrbtr8rg3dxqOsNZB5+nyisXF+74m71i2NpZuoJs+/ug7o2Sc/wz0adxAMwIKqXqvcC4Y3crrOvzqJfy6v/KzeVHydZjA419h/QbY/deM89vIN1wmwbMDmZjUethb4B94WaMmcdQ5YuuJFA7NxMx9p687p2vod16zyZpfXvkzDatyYJ0L/aNxBMIAKSr5UAjTvJIDCFfL8NdjUMGh8/1qkC3x5MI1DQTq+bikv2TCrkyrPmnUaq7/uDealZrcd2FS4LOhXz22/Nozb65HPNztDV7hmYTfufR2+f18XOxaNbqJp0/jlut1sxMskxZfGIW+20biDIPjTaI1bfvfltxGNOwiCP41s3PRk3Pup5dOJxh0EwZ+mfhkCXlpJjVu+/PAN1C/xROP+fP79+w/ZZGrHUiwB5QAAAABJRU5ErkJggg==" alt="" width="366" height="33" vspace="0" hspace="0" border="0" style="width:366px;height:33px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; For creatinine in mg/dL:</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="image3.png" o:spid="_x0000_s1026" type="#_x0000_t75" style='position:absolute;
  margin-left:38.3pt;margin-top:8.2pt;width:240pt;height:24.75pt;z-index:251659264;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><img src="data:image/png;base64,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" alt="" width="320" height="33" vspace="0" hspace="0" border="0" style="width:320px;height:33px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>This method is recommended when assessing patients&#39; CrCL prior to and during Lixiana treatment.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p><em>&nbsp;</em></p><p>In patients with mild renal impairment (CrCL &gt; 50 &ndash; 80 mL/min), the recommended dose is 60 mg Lixiana once daily.</p><p>&nbsp;</p><p>In patients with moderate or severe renal impairment (CrCL 15 &ndash; 50 mL/min), the recommended dose is 30 mg Lixiana once daily (see section 5.2).</p><p>&nbsp;</p><p>In patients with end stage renal disease (ESRD) (CrCL &lt; 15 mL/min) or on dialysis, the use of Lixiana is not recommended (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p><em>&nbsp;</em></p><p>Lixiana is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 4.3).</p><p>&nbsp;</p><p>In patients with severe hepatic impairment Lixiana is not recommended (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p>In patients with mild to moderate hepatic impairment the recommended dose is 60 mg Lixiana once daily (see section 5.2). Lixiana should be used with caution in patients with mild to moderate hepatic impairment (see section 4.4).</p><p>&nbsp;</p><p>Patients with elevated liver enzymes (ALT/AST &gt; 2 x ULN) or total bilirubin &ge; 1.5 x ULN were excluded in clinical trials. Therefore Lixiana should be used with caution in this population (see sections 4.4 and 5.2). Prior to initiating Lixiana, liver function testing should be performed.</p><p>&nbsp;</p><p><em>Body weight</em></p><p><em>&nbsp;</em></p><p>For patients with body weight &le; 60 kg, the recommended dose is 30 mg Lixiana once daily (see section 5.2).</p><p>&nbsp;</p><p><em>Elderly patients</em></p><p><em>&nbsp;</em></p><p>No dose reduction is required (see section 5.2).</p><p>&nbsp;</p><p><em>Gender</em></p><p><em>&nbsp;</em></p><p>No dose reduction is required (see section 5.2).</p><p>&nbsp;</p><p><em>Concomitant use of Lixiana with P-glycoprotein (P-gp) inhibitors</em></p><p><em>&nbsp;</em></p><p>In patients concomitantly taking Lixiana and the following P-gp inhibitors: ciclosporin, dronedarone, erythromycin, or ketoconazole, the recommended dose is 30 mg Lixiana once daily (see section 4.5).</p><p>&nbsp;</p><p>No dose reduction is required for concomitant use of amiodarone, quinidine or verapamil (see section 4.5). The use of Lixiana with other P-gp inhibitors including HIV protease inhibitors has not been studied.</p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p>The safety and efficacy of Lixiana in children and adolescents less than 18 years of age have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>For oral use.</p><p>&nbsp;</p><p>Lixiana can be taken with or without food (see section 5.2).</p><p>&nbsp;</p><p>For patients who are unable to swallow whole tablets, Lixiana tablets may be crushed and mixed with water or apple puree and immediately administered orally (see section 5.2).</p><p>Alternatively, Lixiana tablets may be crushed and suspended in a small amount of water and immediately delivered through a gastric tube after which it should be flushed with water (see section 5.2). Crushed Lixiana tablets are stable in water and apple puree for up to 4 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

•	Clinically significant active bleeding.

•	Hepatic disease associated with coagulopathy and clinically relevant bleeding risk.

•	Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.

•	Uncontrolled severe hypertension.

•	Concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH), low molecular weightheparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexilate, rivaroxaban, apixaban etc.) except under specific circumstances of switching oral anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5).
 
•	Pregnancy and breast-feeding (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lixiana 15 mg is not indicated as monotherapy, as it may result in decreased efficacy. It is only indicated in theprocess of switching from Lixiana 30 mg (patients with one or more clinical factors for increased exposure; seetable 1) to VKA, together with an appropriate VKA dose (see table 2, section 4.2).</p><p>&nbsp;</p><p><em><u>Haemorrhagic risk</u></em></p><p><em>&nbsp;</em></p><p>Edoxaban increases the risk of bleeding and can cause serious, potentially fatal bleeding. Lixiana, like other anticoagulants, is recommended to be used with caution in patients with increased risk of bleeding. Lixiana administration should be discontinued if severe haemorrhage occurs (see sections 4.8 and 4.9).</p><p>&nbsp;</p><p>In the clinical studies mucosal bleedings (e.g. epistaxis, gastrointestinal, genitourinary) and anaemia were seen more frequently during long term edoxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding, as judged to be appropriate.</p><p>&nbsp;</p><p>Several sub-groups of patients, as detailed below, are at increased risk of bleeding. These patients are to be carefully monitored for signs and symptoms of bleeding complications and anaemia after initiation of treatment (see section 4.8). Any unexplained fall in haemoglobin or blood pressure should lead to a search for a bleeding site.</p><p>&nbsp;</p><p>The anticoagulant effect of edoxaban cannot be reliably monitored with standard laboratory testing. A specific anticoagulant reversal agent for edoxaban is not available (see section 4.9).</p><p>Haemodialysis does not significantly contribute to edoxaban clearance (see section 5.2).</p><p>&nbsp;</p><p><em><u>Elderly patients</u></em></p><p><em>&nbsp;</em></p><p>The co-administration of Lixiana with ASA in elderly patients should be used cautiously because of a potentially higher bleeding risk (see section 4.5).</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p><em>&nbsp;</em></p><p>The plasma AUC for subjects with mild (CrCL &gt; 50 - 80 mL/min), moderate (CrCL 30 - 50 mL/min) and severe (CrCL &lt; 30 mL/min but not undergoing dialysis) renal impairment was increased by 32%, 74%, and 72%, respectively, relative to subjects with normal renal function (see section 4.2 for dose reduction).</p><p>&nbsp;</p><p>In patients with end stage renal disease or on dialysis, Lixiana is not recommended (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><em><u>Renal function in NVAF</u></em></p><p><em>&nbsp;</em></p><p>A trend towards decreasing efficacy with increasing creatinine clearance was observed for edoxaban compared to well-managed warfarin (see section 5.1). Therefore, edoxaban should only be used in patients with NVAF and high creatinine clearance after a careful evaluation of the individual thromboembolic and bleeding risk.</p><p>&nbsp;</p><p>Assessment of renal function: CrCL should be monitored at the beginning of the treatment in all patients and afterwards when clinically indicated (see section 4.2).</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p><em>&nbsp;</em></p><p>Lixiana is not recommended in patients with severe hepatic impairment (see sections 4.2 and 5.2).</p><p>Lixiana should be used with caution in patients with mild or moderate hepatic impairment (see section 4.2).</p><p>&nbsp;</p><p>Patients with elevated liver enzymes (ALT/AST &gt; 2 x ULN) or total bilirubin &ge; 1.5 x ULN were excluded in clinical trials. Therefore Lixiana should be used with caution in this population (see sections 4.2 and 5.2). Prior to initiating Lixiana, liver function testing should be performed.</p><p>&nbsp;</p><p>Periodic hepatic monitoring is recommended for patients on Lixiana treatment beyond 1 year.</p><p>&nbsp;</p><p><em><u>Discontinuation for surgery and other interventions</u></em></p><p><em>&nbsp;</em></p><p>If anticoagulation must be discontinued to reduce the risk of bleeding with surgical or other procedures, Lixiana should be stopped as soon as possible and preferably at least 24 hours before the procedure.</p><p>&nbsp;</p><p>In deciding whether a procedure should be delayed until 24 hours after the last dose of Lixiana, the increased risk of bleeding should be weighed against the urgency of the intervention. Lixiana should be restarted after the surgical or other procedures as soon as adequate haemostasis has been established, noting that the time to onset of the edoxaban anticoagulant therapeutic effect is 1 &ndash; 2 hours. If oral medicinal products cannot be taken during or after surgical intervention, consider administering a parenteral anticoagulant and then switch to oral once daily Lixiana (see section 4.2).</p><p>&nbsp;</p><p><em><u>Anticoagulants, antiplatelets, thrombolytics and other medicinal products affecting haemostasis</u></em></p><p><em>&nbsp;</em></p><p>Concomitant use of medicines affecting haemostasis may increase the risk of bleeding. These include acetylsalicylic acid (ASA), P2Y12 platelet inhibitors, other antithrombotic agents, fibrinolytic therapy, selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), and chronic nonsteroidal anti-inflammatory drugs (NSAIDs) (see section 4.5).</p><p>&nbsp;</p><p><em><u>Prosthetic heart valves and moderate to severe mitral stenosis</u></em></p><p><em>&nbsp;</em></p><p>Edoxaban has not been studied in patients with mechanical heart valves, in patients during the first 3 months after implantation of a bioprosthetic heart valve, with or without atrial fibrillation, or in patients with moderate to severe mitral stenosis. Therefore, use of edoxaban is not recommended in these patients.</p><p>&nbsp;</p><p><em><u>Haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy</u></em></p><p><em>&nbsp;</em></p><p>Lixiana is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy since the safety and efficacy of edoxaban have not been established in these clinical situations.</p><p>&nbsp;</p><p><em><u>Patients with active cancer</u></em></p><p><em>&nbsp;</em></p><p>Efficacy and safety of edoxaban in the treatment and/or prevention of VTE in patients with active cancer have not been established.</p><p>&nbsp;</p><p><em><u>Laboratory coagulation parameters</u></em></p><p><em>&nbsp;</em></p><p>Although treatment with edoxaban does not require routine monitoring, the effect on anticoagulation can be estimated by a calibrated quantitative anti-Factor Xa assay which may help to inform clinical decisions in particular situations as, e.g. overdose and emergency surgery (see also section 5.2).</p><p>&nbsp;</p><p>Edoxaban prolongs standard clotting tests such as prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT) as a result of FXa inhibition. Changes observed in these clotting tests at the expected therapeutic dose are, however, small, subject to a high degree of variability, and not useful in monitoring the anticoagulation effect of edoxaban.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Edoxaban is predominantly absorbed in the upper gastrointestinal (GI) tract. Thus, medicines or disease conditions that increase gastric emptying and gut motility have the possibility of reducing edoxaban dissolution and absorption.</p><p>&nbsp;</p><p><em><u>P-gp inhibitors</u></em></p><p><em>&nbsp;</em></p><p>Edoxaban is a substrate for the efflux transporter P-gp. In pharmacokinetic (PK) studies, concomitant administration of edoxaban with the P-gp inhibitors: ciclosporin, dronedarone, erythromycin, ketoconazole, quinidine, or verapamil resulted in increased plasma concentrations of edoxaban. Concomitant use of edoxaban with ciclosporin, dronedarone, erythromycin, or ketoconazole requires dose reduction to 30 mg once daily.</p><p>Concomitant use of edoxaban with quinidine, verapamil, or amiodarone does not require dose reduction based on clinical data (see section 4.2).</p><p>&nbsp;</p><p>The use of edoxaban with other P-gp inhibitors including HIV protease inhibitors has not been studied. Lixiana 30 mg once daily must be administered during concomitant use with the following P-gp inhibitors:</p><p>&bull;&nbsp;&nbsp; <em>Ciclosporin: </em>Concurrent administration of a single dose of ciclosporin 500 mg with a single dose of edoxaban 60 mg increased edoxaban AUC and Cmax by 73% and 74%, respectively.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; <em>Dronedarone: </em>Dronedarone 400 mg twice daily for 7 days with a single concomitant dose of edoxaban 60 mg on Day 5 increased edoxaban AUC and Cmax by 85% and 46%, respectively.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; <em>Erythromycin:</em><em> </em>Erythromycin 500 mg four times daily for 8 days with a single concomitant dose of edoxaban 60 mg on Day 7 increased the edoxaban AUC and Cmax by 85% and 68%, respectively.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; <em>Ketoconazole: </em>Ketoconazole 400 mg once daily for 7 days with a single concomitant dose of edoxaban 60 mg on Day 4, increased edoxaban AUC and Cmax by 87% and 89%, respectively.</p><p>&nbsp;</p><p>Lixiana 60 mg once daily is recommended during concomitant use with the following P-gp inhibitors:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; <em>Quinidine:</em><em> </em>Quinidine 300 mg once daily on Days 1 and 4 and three times daily on Days 2 and 3, with a single concomitant dose of edoxaban 60 mg on Day 3, increased edoxaban AUC over 24 hours by 77% and Cmax by 85%, respectively.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; <em>Verapamil: </em>Verapamil 240 mg once daily for 11 days with a single concomitant dose of edoxaban 60 mg onDay 10 increased the edoxaban AUC and Cmax by approximately 53%.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; <em>Amiodarone: </em>Co-administration of amiodarone 400 mg once daily with edoxaban 60 mg once daily increased AUC by 40% and Cmax by 66%. This was not considered clinically significant. In ENGAGE AF-TIMI 48 study in NVAF, efficacy and safety results were similar for subjects with and without concomitant amiodarone use.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; Clarithromycin: Clarithromycin (500 mg twice daily) for 10 days with a single concomitant dose of edoxaban 60 mg on day 9 increased the edoxaban AUC and Cmax by approximately 53% and 27%, respectively.</p><p>&nbsp;</p><p><em><u>P-gp inducers</u></em></p><p><em>&nbsp;</em></p><p>Co-administration of edoxaban with the P-gp inducer rifampicin led to a decrease in mean edoxaban AUC and a shortened half-life, with possible decreases in its pharmacodynamic effects. The concomitant use of edoxaban</p><p>with other P-gp inducers (e.g. phenytoin, carbamazepine, phenobarbital or St. John&#39;s Wort) may lead to reduced edoxaban plasma concentrations. Edoxaban should be used with caution when co-administered with P-gp inducers.</p><p>&nbsp;</p><p><em><u>P-gp substrates</u></em></p><p><em>&nbsp;</em></p><p><em>Digoxin: </em>Edoxaban 60 mg once daily on days 1 to 14 with coadministration of multiple daily doses of digoxin</p><p>1.25 mg twice daily (days 8 and 9) and 0.25 mg once daily (days 10 to 14) increased the Cmax of edoxaban by 17%, with no significant effect on AUC or renal clearance at steady state. When the effects of edoxaban on digoxin PK were also examined, the Cmax of digoxin increased by approximately 28% and AUC by 7%. This was not considered clinically relevant. No dose modification is necessary when Lixiana is administered with digoxin.</p><p>&nbsp;</p><p><em><u>Anticoagulants, antiplatelets, NSAIDs and SSRIs/SNRIs</u></em></p><p><em>&nbsp;</em></p><p><em>Anticoagulants: </em>Co-administration of edoxaban with other anticoagulants is contraindicated due to increased risk of bleeding (see section 4.3).</p><p>&nbsp;</p><p><em>Acetylsalicylic acid (ASA): </em>Co-administration of ASA (100 mg or 325 mg) and edoxaban increased bleeding time relative to either medicine alone. Co-administration of high dose ASA (325 mg) increased the steady state Cmax and AUC of edoxaban by 35% and 32%, respectively. The concomitant chronic use of high dose ASA (325 mg) with edoxaban is not recommended. Concomitant administration of higher doses than 100 mg ASA should only be performed under medical supervision.</p><p>&nbsp;</p><p>In clinical studies concomitant use of ASA (low dose &le; 100 mg/day), other antiplatelet agents, and thienopyridines was permitted and resulted in approximately a 2-fold increase in major bleeding in comparison with no concomitant use, although to a similar extent in the edoxaban and warfarin groups (see section 4.4). Co- administration of low dose ASA (&le; 100 mg) did not affect the peak or total exposure of edoxaban either after single dose or at steady-state.</p><p>&nbsp;</p><p>Edoxaban can be co-administered with low dose ASA (&le; 100 mg/day).</p><p>&nbsp;</p><p><em>Platelet inhibitors: </em>In ENGAGE AF-TIMI 48 concomitant use of thienopyridines (e.g. clopidogrel) monotherapy was permitted and resulted in increased clinically relevant bleeding although with a lower risk of bleeding on edoxaban compared to warfarin (see section 4.4).</p><p>&nbsp;</p><p>There is very limited experience on the use of edoxaban with dual antiplatelet therapy or fibrinolytic agents.</p><p>&nbsp;</p><p><em>NSAIDs: </em>Co-administration of naproxen and edoxaban increased bleeding time relative to either medicine alone. Naproxen had no effect on the Cmax and AUC of edoxaban. In clinical studies, co-administration of NSAIDs resulted in increased clinically relevant bleeding. Chronic use of NSAIDs with edoxaban is not recommended.</p><p>&nbsp;</p><p>SSRIs/SNRIs: As with other anticoagulants the possibility may exist that patients are at increased risk of bleeding in case of concomitant use with SSRIs or SNRIs due to their reported effect on platelets (see section 4.4).</p><p>&nbsp;</p><p><em><u>Effect of edoxaban on other medicines</u></em></p><p>&nbsp;</p><p>Edoxaban increased the Cmax of concomitantly administered digoxin by 28%; however, the AUC was not affected. Edoxaban had no effect on the Cmax and AUC of quinidine.</p><p>&nbsp;</p><p>Edoxaban decreased the Cmax and AUC of concomitantly administered verapamil by 14% and 16%, respectively.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy category: C</u></strong></p><p><strong>&nbsp;</strong></p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>Safety and efficacy of edoxaban have not been established in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Due to the potential reproductive toxicity, the intrinsic risk of bleeding and the evidence that edoxaban passes the placenta, Lixiana is contraindicated during pregnancy (see section 4.3).</p><p>&nbsp;</p><p>Women of childbearing potential</p><p>The risk of clinically significant uterine bleeding, potentially requiring gynecological surgical interventions, identified with oral anticoagulants including LIXIANA should be assessed in females of reproductive potential and those with abnormal uterine bleeding</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>Safety and efficacy of edoxaban have not been established in breast-feeding women. Data from animals indicate that edoxaban is secreted into breast milk. Therefore Lixiana is contraindicated during breast-feeding (see section 4.3). A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>No specific studies with edoxaban in humans have been conducted to evaluate effects on fertility. In a study on male and female fertility in rats no effects were seen (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lixiana has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SUMMARY OF THE SAFETY&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PROFILE</p><p>&nbsp;</p><p>The safety of edoxaban has been evaluated in two Phase 3 studies including 21,105 patients with NVAF (ENGAGE AF-TIMI 48 study), and 8,292 patients with VTE (DVT and PE) (Hokusai-VTE study).</p><p>&nbsp;</p><p>The average exposure to edoxaban 60 mg (including 30 mg dose reduced) was 2.5 years among 7,012 patients in ENGAGE AF-TIMI 48 and 251 days among 4,118 patients in Hokusai-VTE.</p><p>&nbsp;</p><p>Adverse reactions were experienced by 2,256 (32.2%) of the patients treated with edoxaban 60 mg (30 mg dose reduced) in the ENGAGE AF-TIMI 48 study and 1,249 (30.3%) in the Hokusai-VTE study.</p><p>In both studies, the most common adverse reactions related to bleeding with edoxaban 60 mg based on adjudicated terms included cutaneous soft tissue haemorrhage (up to 5.9%) and epistaxis (up to 4.7%), while vaginal haemorrhage (9.0%) was the most common bleeding-related adverse reaction in Hokusai-VTE only.</p><p>Bleeding can occur at any site and may be severe and even fatal (see section 4.4).</p><p>&nbsp;</p><p>Common other adverse reactions for edoxaban were anaemia, rash and abnormal liver function tests.</p><p><!--[if gte vml 1]><o:wrapblock><v:shape id="_x0000_s1026"
  style='position:absolute;margin-left:35.25pt;margin-top:16.7pt;width:543pt;
  height:.1pt;z-index:-15727104;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page'
  coordorigin="705,334" coordsize="10860,0" path="m705,334r10860,e" filled="f"
  strokecolor="#f8b31f" strokeweight=".72pt">
  <v:path arrowok="t"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="726" height="2" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>TABULATED LIST OF ADVERSE REACTIONS</p><p>&nbsp;</p><p>Table 3 provides the list of adverse reactions from the two pivotal Phase 3 studies in patients with VTE (DVT and PE) (Hokusai-VTE study) and AF (ENGAGE AF-TIMI 48 study) combined for both indications. The adverse reactions are classified by System Organ Class and frequency, using the following convention:</p><p>&nbsp;</p><p>Very common (&ge; 1/10), Common (&ge; 1/100 to &lt; 1/10), Uncommon (&ge; 1/1,000 to &lt; 1/100), Rare (&ge; 1/10,000 to &lt; 1/1,000), Very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Table 3: List of adverse reactions for NVAF and VTE</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactic reaction</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Allergic oedema</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Intracranial haemorrhage (ICH)</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Subarachnoid haemorrhage</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Conjunctival/Scleral haemorrhage</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Intraocular haemorrhage</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pericardial haemorrhage</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Other haemorrhage</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Epistaxis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Haemoptysis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Lower GI haemorrhage</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Upper GI haemorrhage</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Oral/Pharyngeal haemorrhage</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Retroperitoneal haemorrhage</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood bilirubin increased</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gammaglutamyltransferase increased</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood alkaline phosphatase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Transaminases increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cutaneous soft tissue haemorrhage</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Intramuscular haemorrhage (no compartment syndrome)</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Intra-articular haemorrhage</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Macroscopic haematuria/urethral haemorrhage</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Anticoagulant-related nephropathy&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vaginal haemorrhage<sup>1</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Puncture site haemorrhage</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Liver function test abnormal</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Surgical site haemorrhage</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Subdural haemorrhage</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Procedural haemorrhage</p></td><td style="vertical-align:top"><p>Rare</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><sup>1</sup> Reporting rates are based on the female population in clinical trials. Vaginal bleeds were reported commonly in women under the age of 50 years, while it was uncommon in women over the age of 50 years.</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1027" style='position:absolute;margin-left:35.25pt;margin-top:15.65pt;
  width:543pt;height:.1pt;z-index:-15726592;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page'
  coordorigin="705,313" coordsize="10860,0" path="m705,313r10860,e" filled="f"
  strokecolor="#f8b31f" strokeweight=".72pt">
  <v:path arrowok="t"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="726" height="2" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>DESCRIPTION OF SELECTED ADVERSE REACTIONS</p><p>&nbsp;</p><p>Due to the pharmacological mode of action, the use of Lixiana may be associated with an increased risk of occult or overt bleeding from any tissue or organ which may result in post haemorrhagic anaemia. The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anaemia (see section 4.9 Management of bleeding). In the clinical studies mucosal bleedings</p><p>&nbsp;</p><p>(e.g. epistaxis, gastrointestinal, genitourinary) and anaemia were seen more frequently during long term edoxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding, as judged to be appropriate. The risk of bleedings may be increased in certain patient groups e.g. those patients with uncontrolled severe arterial hypertension and/or on concomitant treatment affecting haemostasis (see Haemorrhagic risk in section 4.4). Menstrual bleeding may be intensified and/or prolonged. Haemorrhagic complications may present as weakness, paleness, dizziness, headache or unexplained swelling, dyspnoea, and unexplained shock.</p><p>&nbsp;</p><p>Known complications secondary to severe bleeding such as compartment syndrome and renal failure due to hypoperfusion have been reported for Lixiana. Therefore, the possibility of haemorrhage is to be considered in evaluating the condition in any anticoagulated patient.</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1028" style='position:absolute;margin-left:35.25pt;margin-top:16.6pt;
  width:543pt;height:.1pt;z-index:-15726080;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page'
  coordorigin="705,332" coordsize="10860,0" path="m705,332r10860,e" filled="f"
  strokecolor="#f8b31f" strokeweight=".72pt">
  <v:path arrowok="t"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="726" height="2" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>PAEDIATRIC POPULATION</p><p>&nbsp;</p><p>The safety and efficacy of Lixiana in children and adolescents less than 18 years of age have not been established. No data are available.</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1029" style='position:absolute;margin-left:35.25pt;margin-top:16pt;
  width:543pt;height:.1pt;z-index:-15725568;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page'
  coordorigin="705,320" coordsize="10860,0" path="m705,320r10860,e" filled="f"
  strokecolor="#f8b31f" strokeweight=".72pt">
  <v:path arrowok="t"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="726" height="2" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>OTHER SPECIAL POPULATION</p><p>&nbsp;</p><p>Renal impairment</p><p><strong>&nbsp;</strong></p><p>In patients with mild renal impairment (CrCL &gt; 50 &ndash; 80 mL/min), the recommended dose is 60 mg Lixiana once daily.</p><p>&nbsp;</p><p>In patients with moderate or severe renal impairment (CrCL 15 &ndash; 50 mL/min), the recommended dose is 30 mg Lixiana once daily (see section 5.2).</p><p>&nbsp;</p><p>In patients with end stage renal disease (ESRD) (CrCL &lt; 15 mL/min) or on dialysis, the use of Lixiana is not recommended (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p>Hepatic impairment</p><p><strong>&nbsp;</strong></p><p>Lixiana is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 4.3).</p><p>&nbsp;</p><p>In patients with severe hepatic impairment Lixiana is not recommended (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p>In patients with mild to moderate hepatic impairment the recommended dose is 60 mg Lixiana once daily (see section 5.2). Lixiana should be used with caution in patients with mild to moderate hepatic impairment (see section 4.4).</p><p>&nbsp;</p><p>Patients with elevated liver enzymes (ALT/AST &gt; 2 x ULN) or total bilirubin &ge; 1.5 x ULN were excluded in clinical trials. Therefore Lixiana should be used with caution in this population (see sections 4.4 and 5.2). Prior to initiating Lixiana, liver function testing should be performed.</p><p>&nbsp;</p><p>Body weight</p><p><strong>&nbsp;</strong></p><p>For patients with body weight &le; 60 kg, the recommended dose is 30 mg Lixiana once daily (see section 5.2).</p><p>&nbsp;</p><p>Elderly patients</p><p><strong>&nbsp;</strong></p><p>No dose reduction is required (see section 5.2).</p><p>&nbsp;</p><p>Gender</p><p>No dose reduction is required (see section 5.2).</p><p>&nbsp;</p><p>Concomitant use of Lixiana with P-glycoprotein (P-gp) inhibitors</p><p><strong>&nbsp;</strong></p><p>In patients concomitantly taking Lixiana and the following P-gp inhibitors: ciclosporin, dronedarone, erythromycin, or ketoconazole, the recommended dose is 30 mg Lixiana once daily (see section 4.5).</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1030" style='position:absolute;left:0;text-align:left;
  margin-left:35.25pt;margin-top:58.7pt;width:543pt;height:.1pt;z-index:-15725056;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="705,1174" coordsize="10860,0"
  path="m705,1174r10860,e" filled="f" strokecolor="#f8b31f" strokeweight=".72pt">
  <v:path arrowok="t"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="726" height="2" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br />No dose reduction is required for concomitant use of amiodarone, quinidine or verapamil (see section 4.5). The use of Lixiana with other P-gp inhibitors including HIV protease inhibitors has not been studied.</p><p>&nbsp;</p><p>REPORTING OF SUSPECTED ADVERSE REACTIONS</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Saudi Arabia:</strong>&nbsp;&nbsp; <!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1031" type="#_x0000_t202" style='position:absolute;
  left:0;text-align:left;margin-left:30.35pt;margin-top:30.2pt;width:551.4pt;
  height:82.4pt;text-indent:0;z-index:-15724544;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page' filled="f"
  strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-left:5.4pt;line-height:13.8pt;
     mso-line-height-rule:exactly'>The<span style='letter-spacing:-.55pt'> </span>National
     Pharmacovigilance<span style='letter-spacing:-.35pt'> </span>Centre<span
     style='letter-spacing:-.35pt'> </span>(NPC)<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.25pt'><span style='font-size:10.0pt;
     mso-bidi-font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     <p class=MsoBodyText style='margin-left:12.35pt;text-indent:-7.0pt;
     mso-list:l3 level1 lfo1;tab-stops:12.4pt'><![if !supportLists]><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>SFDA<span style='letter-spacing:
     -.15pt'> </span>Call<span style='letter-spacing:-.05pt'> </span>Center:<span
     style='letter-spacing:-.05pt'> </span>19999<o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:12.35pt;text-indent:-7.0pt;
     mso-list:l3 level1 lfo1;tab-stops:12.4pt'><![if !supportLists]><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>E-mail:<span
     style='letter-spacing:-.05pt'> </span><a href="mailto:npc.drug@sfda.gov.sa"><span
     style='color:windowtext;text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:5.4pt'>-Website:<span
     style='letter-spacing:-.1pt'> </span>https://ade.sfda.gov.sa<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="742" height="116" alt="Text Box: The National Pharmacovigilance Centre (NPC)

-	SFDA Call Center: 19999
-	E-mail: npc.drug@sfda.gov.sa
-Website: https://ade.sfda.gov.sa
" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United Arab Emirates</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1032" type="#_x0000_t202" style='position:absolute;margin-left:19.55pt;
  margin-top:12.35pt;width:549.6pt;height:69.5pt;z-index:-15724032;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:0in;margin-right:322.9pt;
     margin-bottom:0in;margin-left:5.15pt;margin-bottom:.0001pt'>Pharmacovigilance<span
     style='letter-spacing:-.2pt'> </span>&amp;<span style='letter-spacing:
     -.1pt'> </span>Medical<span style='letter-spacing:-.1pt'> </span>Device<span
     style='letter-spacing:-.15pt'> </span>section<span style='letter-spacing:
     -2.85pt'> </span>P.O.Box: 1853<o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:5.15pt'>Tel:<span
     style='letter-spacing:-.1pt'> </span>80011111<o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:5.15pt'>Email:<span
     style='letter-spacing:-.05pt'> </span><a href="mailto:pv@mohap.gov.ae"><span
     style='color:windowtext;text-decoration:none;text-underline:none'>pv@mohap.gov.ae</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:5.15pt'>Drug<span
     style='letter-spacing:-.15pt'> </span>Department<span style='letter-spacing:
     -.1pt'> </span>Ministry<span style='letter-spacing:-.15pt'> </span>of<span
     style='letter-spacing:-.15pt'> </span>Health<span style='letter-spacing:
     -.15pt'> </span>&amp;<span style='letter-spacing:-.1pt'> </span>Prevention<span
     style='letter-spacing:-.05pt'> </span>Dubai –<span style='letter-spacing:
     -.1pt'> </span>UAE<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="739" height="99" alt="Text Box: Pharmacovigilance &amp; Medical Device section P.O.Box: 1853
Tel: 80011111
Email: pv@mohap.gov.ae
Drug Department Ministry of Health &amp; Prevention Dubai – UAE
" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC states /other countries</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1033" type="#_x0000_t202" style='position:absolute;margin-left:25.4pt;
  margin-top:7.35pt;width:443.4pt;height:17.2pt;z-index:-15723520;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:1.15pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.4pt;margin-bottom:.0001pt'>-Please contact the relevant<span
     style='letter-spacing:.05pt'> </span>competent authority.<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="597" height="29" alt="Text Box: -Please contact the relevant competent authority." src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose with edoxaban may lead to haemorrhage. Experience with overdose cases is very limited. A specific antidote antagonising the pharmacodynamic effect of edoxaban is not available.</p><p>Early administration of activated charcoal may be considered in case of edoxaban overdose to reduce absorption. This recommendation is based on standard treatment of drug overdose and data available with similar compounds, as the use of activated charcoal to reduce absorption of edoxaban has not been specifically studied in the edoxaban clinical programme.</p><p>&nbsp;</p><p><u>Management of bleeding</u></p><p>&nbsp;</p><p>Should a bleeding complication arise in a patient receiving edoxaban, the next edoxaban administration should be delayed or treatment should be discontinued as appropriate. Edoxaban has a half-life of approximately 10 to 14 hours (see section 5.2). Management should be individualised according to the severity and location of the</p><p>&nbsp;</p><p>haemorrhage. Appropriate symptomatic treatment could be used as needed, such as mechanical compression (e.g. for severe epistaxis), surgical haemostasis with bleeding control procedures, fluid replacement and haemodynamic support, blood products (packed red cells or fresh frozen plasma, depending on associated anaemia or coagulopathy) or platelets.</p><p>&nbsp;</p><p>For life-threatening bleeding that cannot be controlled with the measures such as transfusion or haemostasis, the administration of a 4-factor prothrombin complex concentrate (PCC) at 50 IU/kg has been shown to reverse the effects of Lixiana 30 minutes after completing the infusion.</p><p>&nbsp;</p><p>Recombinant factor VIIa (r-FVIIa) can also be considered. However, there is limited clinical experience with the use of this product in individuals receiving edoxaban.</p><p>&nbsp;</p><p>Depending on local availability, a consultation with a coagulation expert should be considered in case of major bleedings.</p><p>&nbsp;</p><p>Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of edoxaban.</p><p>&nbsp;</p><p>There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in individuals receiving edoxaban. There is neither scientific rationale for benefit nor experience with the use of systemic haemostatics (desmopressin, aprotinin) in individuals receiving edoxaban. Due to the high plasma protein binding edoxaban is not expected to be dialysable.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other antithrombotic agents, ATC code: B01AF03 <u>Mechanism of action</u></p><p>Edoxaban is a highly selective, direct and reversible inhibitor of factor Xa, the serine protease located in the final common pathway of the coagulation cascade. Edoxaban inhibits free factor Xa, and prothrombinase activity. Inhibition of factor Xa in the coagulation cascade reduces thrombin generation, prolongs clotting time and reduces the risk of thrombus formation.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Edoxaban produces rapid onset of pharmacodynamic effects within 1 - 2 hours, which corresponds with peak edoxaban exposure (Cmax). The pharmacodynamic effects measured by anti-factor Xa assay are predictable and correlate with the dose and the concentration of edoxaban. As a result of FXa inhibition, edoxaban also prolongs clotting time in tests such as prothrombin time (PT), and activated partial thromboplastin time (aPTT). Changes observed in these clotting tests are expected at the therapeutic dose, however, these changes are small, subject to a high degree of variability, and not useful in monitoring the anticoagulation effect of edoxaban.</p><p>&nbsp;</p><p><em>Effects of coagulation markers when switching from rivaroxaban, dabigatran, or apixaban to edoxaban</em></p><p><em>&nbsp;</em></p><p>In clinical pharmacology studies, healthy subjects received rivaroxaban 20 mg once daily, dabigatran 150 mg twice daily, or apixaban 5 mg twice daily, followed by a single dose of edoxaban 60 mg on Day 4. The effect on prothrombin time (PT) and other coagulation biomarkers (e.g. anti-FXa, aPTT) was measured. Following the switch to edoxaban on Day 4 the PT was equivalent to Day 3 of rivaroxaban and apixaban. For dabigatran higher aPTT activity was observed after edoxaban administration with prior dabigatran treatment compared to that after treatment with edoxaban alone. This is considered to be due to the carry-over effect of dabigatran treatment, however, this did not lead to a prolongation of bleeding time.</p><p>&nbsp;</p><p>Based on these data, when switching from these anticoagulants to edoxaban, the first dose of edoxaban can be initiated at the time of the next scheduled dose of the previous anticoagulant (see section 4.2).</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em>Prevention of stroke and systemic embolism</em></p><p><em>&nbsp;</em></p><p>The edoxaban clinical programme for atrial fibrillation was designed to demonstrate the efficacy and safety of two dose groups of edoxaban compared to warfarin for the prevention of stroke and systemic embolism in subjects with nonvalvular atrial fibrillation and at moderate to high risk of stroke and systemic embolic events (SEE).</p><p>&nbsp;</p><p>In the pivotal ENGAGE AF-TIMI 48 study (an event-driven, Phase 3, multi-centre, randomised, double-blind double-dummy parallel-group study), 21,105 subjects, with a mean CHADS2 score of 2.8, were randomised to either edoxaban 30 mg once daily treatment group, or edoxaban 60 mg once daily treatment group or warfarin. Subjects in both edoxaban treatment groups had their dose halved if one or more of the following clinical factors were present: moderate renal impairment (CrCL 30 &ndash; 50 mL/min), low body weight (&le; 60 kg) or concomitant use of specific P-gp inhibitors (verapamil, quinidine, dronedarone).</p><p>&nbsp;</p><p>The primary efficacy endpoint was the composite of stroke and SEE. Secondary efficacy endpoints included: Composite of stroke, SEE, and cardiovascular (CV) mortality; major adverse cardiovascular event (MACE), which is the composite of non-fatal MI, non-fatal stroke, non-fatal SEE, and death due to CV cause or bleeding; composite of stroke, SEE, and all-cause mortality.</p><p>&nbsp;</p><p>The median study drug exposure for both the edoxaban 60 mg and 30 mg treatment groups was 2.5 years. The median study follow-up for both the edoxaban 60 mg and 30 mg treatment groups was 2.8 years. The median subject-year exposure was 15,471, and 15,840 for the 60 mg and 30 mg treatment groups, respectively; and the median subject-year follow-up was 19,191 and 19,216 for the 60 mg and 30 mg treatment groups, respectively.</p><p>&nbsp;</p><p>In the warfarin group, the median TTR (time in therapeutic range, INR 2.0 to 3.0) was 68.4%.</p><p>&nbsp;</p><p>The main analysis of efficacy was aimed to show the non-inferiority of edoxaban versus warfarin on first stroke or SEE that occurred during treatment or within 3 days from the last dose taken in the modified intention-to- treat (mITT) population. Edoxaban 60 mg was non-inferior to warfarin for the primary efficacy endpoint of stroke or SEE (upper limit of the 97.5% CI of the HR was below the pre-specified non-inferiority margin of 1.38) (Table 4).</p><p>&nbsp;</p><p>Table 4: Strokes and Systemic Embolic Events in the ENGAGE AF&ndash;TIMI 48 Study - mITT, on- treatment</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Primary Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Edoxaban 60 mg</strong></p><p><strong>(30 mg Dose Reduced) (N = 7,012)</strong></p></td><td style="vertical-align:top"><p><strong>Warfarin (N = 7,012)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>First Stroke/SEE</strong><sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>182</p></td><td style="vertical-align:top"><p>232</p></td></tr><tr><td style="vertical-align:top"><p>Event Rate (%/yr)<sup>b</sup></p></td><td style="vertical-align:top"><p>1.18</p></td><td style="vertical-align:top"><p>1.50</p></td></tr><tr><td style="vertical-align:top"><p>HR (97.5% CI)</p></td><td style="vertical-align:top"><p>0.79 (0.63, 0.99)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>p-value for non-inferiority<sup>c</sup></p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>First Ischaemic Stroke</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>135</p></td><td style="vertical-align:top"><p>144</p></td></tr><tr><td style="vertical-align:top"><p>Event Rate (%/yr)<sup>b</sup></p></td><td style="vertical-align:top"><p>0.87</p></td><td style="vertical-align:top"><p>0.93</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)</p></td><td style="vertical-align:top"><p>0.94 (0.75, 1.19)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>First Haemorrhagic Stroke</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>76</p></td></tr><tr><td style="vertical-align:top"><p>Event Rate (%/yr)<sup>b</sup></p></td><td style="vertical-align:top"><p>0.26</p></td><td style="vertical-align:top"><p>0.49</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)</p></td><td style="vertical-align:top"><p>0.53 (0.36, 0.78)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>First SEE</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>n (%/yr)<sup>a</sup></p></td><td style="vertical-align:top"><p>8 (0.05)</p></td><td style="vertical-align:top"><p>13 (0.08)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)</p></td><td style="vertical-align:top"><p>0.62 (0.26, 1.50)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Abbreviations: HR = Hazard Ratio versus warfarin, CI = Confidence Interval, n = number of events, mITT = modified Intent To Treat, N = number of subjects in mITT population, SEE = Systemic Embolic Event, yr = year.</p><p>&nbsp;</p><p><sup>a</sup> A subject can be represented in multiple rows.</p><p>&nbsp;</p><p><sup>b</sup> The event rate (%/yr) is calculated as number of events/subject-year exposure.</p><p>&nbsp;</p><p><sup>c</sup> The two-sided p-value is based on the non-inferiority margin of 1.38.</p><p>&nbsp;</p><p>During the overall study period in the ITT population (analysis set to show superiority), adjudicated stroke or SEE occurred in 296 subjects in the edoxaban 60 mg group (1.57% per year), and 337 subjects in the warfarin group (1.80% per year). Compared to warfarin-treated subjects, the HR in the edoxaban 60 mg group was 0.87 (99% CI: 0.71, 1.07, p = 0.08 for superiority).</p><p>&nbsp;</p><p>In subgroup analyses, for subjects in the 60 mg treatment group who were dose reduced to 30 mg in the ENGAGE AF-TIMI 48 study (for body weight &le; 60 kg, moderate renal impairment, or concomitant use of P-gp inhibitors), the event rate was: 2.29% per year for the primary endpoint, compared to the event rate of 2.66% per year for the matching subjects in the warfarin group [HR (95% CI): 0.86 (0.66, 1.13)].</p><p>&nbsp;</p><p>The efficacy results for pre-specified major subgroups (with dose reduction as required), including age, body weight, gender, status of renal function, prior stroke or TIA, diabetes and P-gp inhibitors were generally consistent with the primary efficacy results for the overall population studied in the trial.</p><p>&nbsp;</p><p>The Hazard Ratio (Edoxaban 60 mg vs. warfarin) for the primary endpoint in the centres with a lower average time of INR in the target range (INR TTR) for warfarin was 0.73 &ndash; 0.80 for the lowest 3 quartiles (INR TTR &le; 57.7% to &le; 73.9%). It was 1.07 in centres with the best control of warfarin therapy (4<sup>th</sup> quartile with &gt; 73.9% of INR values in the therapeutic range).</p><p>&nbsp;</p><p>There was a statistically significant interaction between the effect of edoxaban versus warfarin on the main study outcome (stroke/SEE) and renal function (p-value 0.0042; mITT, overall study period).</p><p>&nbsp;</p><p>Table 5 shows ischaemic strokes/SEE by creatinine clearance category in NVAF patients in ENGAGE AF- TIMI 48. There is a decreasing event rate at increasing CrCL in both treatment groups.</p><p>&nbsp;</p><p>Table 5: Number of Ischaemic Strokes/SEE by creatinine clearance category in ENGAGE AF-TIMI 48, mITT Analysis Set Overall Study</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>CrCL</strong></p><p><strong>subgroup (mL/min</strong></p><p><strong>)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Edoxaban 60 mg</strong></p><p><strong>&nbsp;</strong></p><p><strong>(N = 7,012)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Warfarin</strong></p><p><strong>&nbsp;</strong></p><p><strong>(N = 7,012)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>Number of Events</strong></p></td><td style="vertical-align:top"><p><strong>Event rate</strong></p><p><strong>&nbsp;</strong></p><p><strong>(%/year)</strong></p></td><td style="vertical-align:top"><p><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>Number of Events</strong></p></td><td style="vertical-align:top"><p><strong>Event rate</strong></p><p><strong>&nbsp;</strong></p><p><strong>(%/year)</strong></p></td><td style="vertical-align:top"><p><strong>HR (95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&ge; 30 to &le; 50</p></td><td style="vertical-align:top"><p>1,302</p></td><td style="vertical-align:top"><p>63</p></td><td style="vertical-align:top"><p>1.89</p></td><td style="vertical-align:top"><p>1,305</p></td><td style="vertical-align:top"><p>67</p></td><td style="vertical-align:top"><p>2.05</p></td><td style="vertical-align:top"><p>0.93 (0.66,</p><p>1.31)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 50 to &le; 70</p></td><td style="vertical-align:top"><p>2,093</p></td><td style="vertical-align:top"><p>85</p></td><td style="vertical-align:top"><p>1.51</p></td><td style="vertical-align:top"><p>2,106</p></td><td style="vertical-align:top"><p>95</p></td><td style="vertical-align:top"><p>1.70</p></td><td style="vertical-align:top"><p>0.88 (0.66,</p><p>1.18)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 70 to &le; 90</p></td><td style="vertical-align:top"><p>1,661</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>0.99</p></td><td style="vertical-align:top"><p>1,703</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>1.08</p></td><td style="vertical-align:top"><p>0.92 (0.61,</p><p>1.37)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 90 to &le; 110</p></td><td style="vertical-align:top"><p>927</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>1.08</p></td><td style="vertical-align:top"><p>960</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>0.98</p></td><td style="vertical-align:top"><p>1.10 (0.64,</p><p>1.89)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 110 to &le; 130</p></td><td style="vertical-align:top"><p>497</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>1.01</p></td><td style="vertical-align:top"><p>469</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.78</p></td><td style="vertical-align:top"><p>1.27 (0.57,</p><p>2.85)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 130</p></td><td style="vertical-align:top"><p>462</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.78</p></td><td style="vertical-align:top"><p>418</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>0.25</p></td><td style="vertical-align:top"><p>--<sup>*</sup></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Abbreviations: N = number of subjects; mITT population overall study period; n = number of patients in subgroup</p><p>&nbsp;</p><p>*HR not computed if number of events &lt; 5 in one treatment group.</p><p>&nbsp;</p><p>Within renal function subgroups, results for the secondary efficacy endpoints were consistent with those for the primary endpoint.</p><p>&nbsp;</p><p>Superiority testing was performed on the ITT Overall Study Period.</p><p>&nbsp;</p><p>Stroke and SEE occurred in fewer subjects in the edoxaban 60 mg treatment group than in the warfarin group (1.57% and 1.80% per year, respectively), with a HR of 0.87 (99% CI: 0.71, 1.07, p = 0.0807 for superiority).</p><p>&nbsp;</p><p>The pre-specified composite endpoints for the comparison of the edoxaban 60 mg treatment group to warfarin for stroke, SEE, and CV mortality HR (99% CI) was 0.87 (0.76, 0.99), MACE 0.89 (0.78, 1.00), and stroke,</p><p>SEE, and all-cause mortality 0.90 (0.80, 1.01).</p><p>&nbsp;</p><p>The results for all-cause mortality (adjudicated deaths) in the ENGAGE AF-TIMI 48 study were 769 (3.99% per year) for subjects taking edoxaban 60 mg (30 mg dose reduced) as opposed to 836 (4.35% per year) for warfarin [HR (95% CI): 0.91 (0.83, 1.01)].</p><p>&nbsp;</p><p>All-cause mortality (adjudicated deaths) per renal subgroups (edoxaban vs. warfarin): CrCL 30 to &le; 50 mL/min [HR (95% CI): 0.81 (0.68, 0.97)]; CrCL &gt; 50 to &lt; 80 mL/min [HR (95% CI): 0.87 (0.75, 1.02)]; CrCL &ge; 80</p><p>mL/min [HR (95% CI): 1.15 (0.95, 1.40)].</p><p>&nbsp;</p><p>Edoxaban 60 mg (30 mg dose reduced) resulted in a lower rate of cardiovascular mortality compared to warfarin [HR (95% CI): 0.86 (0.77, 0.97)].</p><p>&nbsp;</p><p>Adjudicated efficacy cardiovascular mortality per renal subgroups (edoxaban vs. warfarin): CrCL 30 to &le; 50 mL/min [HR (95% CI): 0.80 (0.65, 0.99)]; CrCL &gt; 50 to &lt; 80 mL/min [HR (95% CI): 0.75 (0.62, 0.90)]; CrCL</p><p>&ge; 80 mL/min [HR (95% CI): 1.16 (0.92, 1.46)].</p><p>&nbsp;</p><p><em><u>Safety in patients with NVAF in ENGAGE AF-TIMI 48</u></em></p><p><em>&nbsp;</em></p><p>The primary safety endpoint was major bleeding.</p><p>&nbsp;</p><p>There was a significant risk reduction in favour of the edoxaban 60 mg treatment group compared with the warfarin group in major bleeding (2.75%, and 3.43% per year, respectively) [HR (95% CI): 0.80 (0.71, 0.91); p</p><p>= 0.0009], ICH (0.39%, and 0.85% per year, respectively) [HR (95% CI): 0.47 (0.34, 0.63); p &lt; 0.0001], and</p><p>other types of bleeding (Table 6).</p><p>&nbsp;</p><p>The reduction in fatal bleeds was also significant for the edoxaban 60 mg treatment group compared with the warfarin group (0.21%, and 0.38%) [HR (95% CI): 0.55 (0.36, 0.84); p = 0.0059 for superiority], primarily because of the reduction in fatal ICH bleeds [HR (95% CI): 0.58 (0.35, 0.95); p = 0.0312].</p><p>&nbsp;</p><p>Table 6: Bleeding Events in ENGAGE AF-TIMI 48 Study - Safety Analysis On-Treatment</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Edoxaban 60 mg</strong></p><p><strong>(30 mg Dose Reduced) (N = 7,012)</strong></p></td><td style="vertical-align:top"><p><strong>Warfarin (N = 7,012)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Major Bleeding</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>418</p></td><td style="vertical-align:top"><p>524</p></td></tr><tr><td style="vertical-align:top"><p>Event rate (%/yr)<sup>a</sup></p></td><td style="vertical-align:top"><p>2.75</p></td><td style="vertical-align:top"><p>3.43</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)</p></td><td style="vertical-align:top"><p>0.80 (0.71, 0.91)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td style="vertical-align:top"><p>0.0009</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ICH<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>132</p></td></tr><tr><td style="vertical-align:top"><p>Event rate (%/yr)<sup>a</sup></p></td><td style="vertical-align:top"><p>0.39</p></td><td style="vertical-align:top"><p>0.85</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)</p></td><td style="vertical-align:top"><p>0.47 (0.34, 0.63)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Fatal Bleeding</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>59</p></td></tr><tr><td style="vertical-align:top"><p>Event rate (%/yr)<sup>a</sup></p></td><td style="vertical-align:top"><p>0.21</p></td><td style="vertical-align:top"><p>0.38</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)</p></td><td style="vertical-align:top"><p>0.55 (0.36, 0.84)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>CRNM Bleeding</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>1,214</p></td><td style="vertical-align:top"><p>1,396</p></td></tr><tr><td style="vertical-align:top"><p>Event rate (%/yr)<sup>a</sup></p></td><td style="vertical-align:top"><p>8.67</p></td><td style="vertical-align:top"><p>10.15</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>HR (95% CI)</p></td><td style="vertical-align:top"><p>0.86 (0.80, 0.93)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Any Confirmed Bleeding<sup>c</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>1,865</p></td><td style="vertical-align:top"><p>2,114</p></td></tr><tr><td style="vertical-align:top"><p>Event rate (%/yr)<sup>a</sup></p></td><td style="vertical-align:top"><p>14.15</p></td><td style="vertical-align:top"><p>16.40</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)</p></td><td style="vertical-align:top"><p>0.87 (0.82, 0.92)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Abbreviations: ICH = Intracranial Haemorrhage, HR = Hazard Ratio versus warfarin,</p><p>&nbsp;</p><p>CI = Confidence Interval, CRNM = Clinically Relevant Non-Major, n = number of subjects with events, N = number of subjects in Safety population, yr = year.</p><p>&nbsp;</p><p><sup>a</sup> The event rate (%/yr) is calculated as number of events/subject-year exposure.</p><p>&nbsp;</p><p><sup>b</sup> ICH includes primary haemorrhagic stroke, subarachnoid haemorrhage, epi-/subdural haemorrhage, and ischaemic stroke with major haemorrhagic conversion. All ICHs reported on the Adjudicated Cerebrovascular and Non-Intracranial bleed eCRF forms confirmed by the adjudicators are included in ICH counts.</p><p>&nbsp;</p><p><sup>c</sup> &#39;Any Confirmed Bleeding&#39; includes those that the adjudicator defined as clinically overt.</p><p>&nbsp;</p><p>Note: A subject can be included in multiple sub-categories if he/she had an event for those categories. The first event of each category is included in the analysis.</p><p>&nbsp;</p><p>Tables 7, 8 and 9 show major, fatal and intracranial bleedings, respectively, by creatinine clearance category in NVAF patients in ENGAGE AF-TIMI 48. There is a decreasing event rate at increasing CrCL in both treatment groups.</p><p>&nbsp;</p><p>Table 7: Number of Major Bleeding Events by creatinine clearance category in ENGAGE AF-TIMI 48, Safety Analysis On-Treatmenta</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>CrCL</strong></p><p><strong>subgroup (mL/min</strong></p><p><strong>)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Edoxaban 60 mg</strong></p><p><strong>&nbsp;</strong></p><p><strong>(N = 7,012)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Warfarin</strong></p><p><strong>&nbsp;</strong></p><p><strong>(N = 7,012)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>Number of Events</strong></p></td><td style="vertical-align:top"><p><strong>Event rate</strong></p><p><strong>&nbsp;</strong></p><p><strong>(%/year)</strong></p></td><td style="vertical-align:top"><p><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>Number of Events</strong></p></td><td style="vertical-align:top"><p><strong>Event rate</strong></p><p><strong>&nbsp;</strong></p><p><strong>(%/year)</strong></p></td><td style="vertical-align:top"><p><strong>HR (95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&ge; 30 to &le; 50</p></td><td style="vertical-align:top"><p>1,302</p></td><td style="vertical-align:top"><p>96</p></td><td style="vertical-align:top"><p>3.91</p></td><td style="vertical-align:top"><p>1,305</p></td><td style="vertical-align:top"><p>128</p></td><td style="vertical-align:top"><p>5.23</p></td><td style="vertical-align:top"><p>0.75 (0.58,</p><p>0.98)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 50 to &le; 70</p></td><td style="vertical-align:top"><p>2,093</p></td><td style="vertical-align:top"><p>148</p></td><td style="vertical-align:top"><p>3.31</p></td><td style="vertical-align:top"><p>2,106</p></td><td style="vertical-align:top"><p>171</p></td><td style="vertical-align:top"><p>3.77</p></td><td style="vertical-align:top"><p>0.88 (0.71,</p><p>1.10)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 70 to &le; 90</p></td><td style="vertical-align:top"><p>1,661</p></td><td style="vertical-align:top"><p>108</p></td><td style="vertical-align:top"><p>2.88</p></td><td style="vertical-align:top"><p>1,703</p></td><td style="vertical-align:top"><p>119</p></td><td style="vertical-align:top"><p>3.08</p></td><td style="vertical-align:top"><p>0.93 (0.72,</p><p>1.21)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 90 to &le; 110</p></td><td style="vertical-align:top"><p>927</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>1.33</p></td><td style="vertical-align:top"><p>960</p></td><td style="vertical-align:top"><p>56</p></td><td style="vertical-align:top"><p>2.48</p></td><td style="vertical-align:top"><p>0.54 (0.34,</p><p>0.84)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 110 to &le; 130</p></td><td style="vertical-align:top"><p>497</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>1.70</p></td><td style="vertical-align:top"><p>469</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>2.14</p></td><td style="vertical-align:top"><p>0.79 (0.44,</p><p>1.42)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 130</p></td><td style="vertical-align:top"><p>462</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>1.18</p></td><td style="vertical-align:top"><p>418</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>2.08</p></td><td style="vertical-align:top"><p>0.58 (0.29,</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.15)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Table 8: Number of Fatal Bleeding Events by creatinine clearance category in ENGAGE AF-TIMI 48, Safety Analysis On-Treatment</strong><strong>a</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>CrCL</strong></p><p><strong>subgroup (mL/min</strong></p><p><strong>)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Edoxaban 60 mg</strong></p><p><strong>&nbsp;</strong></p><p><strong>(N = 7,012)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Warfarin</strong></p><p><strong>&nbsp;</strong></p><p><strong>(N = 7,012)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>Number of Events</strong></p></td><td style="vertical-align:top"><p><strong>Event rate</strong></p><p><strong>&nbsp;</strong></p><p><strong>(%/year)</strong></p></td><td style="vertical-align:top"><p><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>Number of Events</strong></p></td><td style="vertical-align:top"><p><strong>Event rate</strong></p><p><strong>&nbsp;</strong></p><p><strong>(%/year)</strong></p></td><td style="vertical-align:top"><p><strong>HR (95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&ge; 30 to &le; 50</p></td><td style="vertical-align:top"><p>1,302</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>0.36</p></td><td style="vertical-align:top"><p>1,305</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>0.72</p></td><td style="vertical-align:top"><p>0.51 (0.23,</p><p>1.14)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 50 to &le; 70</p></td><td style="vertical-align:top"><p>2,093</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>0.18</p></td><td style="vertical-align:top"><p>2,106</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>0.50</p></td><td style="vertical-align:top"><p>0.35 (0.16,</p><p>0.79)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 70 to &le; 90</p></td><td style="vertical-align:top"><p>1,661</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.26</p></td><td style="vertical-align:top"><p>1,703</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>0.23</p></td><td style="vertical-align:top"><p>1.14 (0.46,</p><p>2.82)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 90 to &le; 110</p></td><td style="vertical-align:top"><p>927</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>0.09</p></td><td style="vertical-align:top"><p>960</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>0.13</p></td><td style="vertical-align:top"><p>--<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 110 to &le; 130</p></td><td style="vertical-align:top"><p>497</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0.08</p></td><td style="vertical-align:top"><p>469</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>0.44</p></td><td style="vertical-align:top"><p>--<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 130</p></td><td style="vertical-align:top"><p>462</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>0.18</p></td><td style="vertical-align:top"><p>418</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0.00</p></td><td style="vertical-align:top"><p>--<sup>*</sup></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Table 9: Number of Intracranial Bleeding Events by creatinine clearance category in ENGAGE AF- TIMI 48, Safety Analysis On-Treatmenta</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>CrCL</strong></p><p><strong>subgroup (mL/min</strong></p><p><strong>)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Edoxaban 60 mg</strong></p><p><strong>&nbsp;</strong></p><p><strong>(N = 7,012)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Warfarin</strong></p><p><strong>&nbsp;</strong></p><p><strong>(N = 7,012)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>Number of Events</strong></p></td><td style="vertical-align:top"><p><strong>Event rate</strong></p><p><strong>&nbsp;</strong></p><p><strong>(%/year)</strong></p></td><td style="vertical-align:top"><p><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>Number of Events</strong></p></td><td style="vertical-align:top"><p><strong>Event rate</strong></p><p><strong>&nbsp;</strong></p><p><strong>(%/year)</strong></p></td><td style="vertical-align:top"><p><strong>HR (95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&ge; 30 to &le; 50</p></td><td style="vertical-align:top"><p>1,302</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0.64</p></td><td style="vertical-align:top"><p>1,305</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>1.40</p></td><td style="vertical-align:top"><p>0.45 (0.25,</p><p>0.81)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 50 to &le; 70</p></td><td style="vertical-align:top"><p>2,093</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>0.42</p></td><td style="vertical-align:top"><p>2,106</p></td><td style="vertical-align:top"><p>51</p></td><td style="vertical-align:top"><p>1.10</p></td><td style="vertical-align:top"><p>0.38 (0.22,</p><p>0.64)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 70 to &le; 90</p></td><td style="vertical-align:top"><p>1,661</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>0.44</p></td><td style="vertical-align:top"><p>1,703</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>0.89</p></td><td style="vertical-align:top"><p>0.50 (0.28,</p><p>0.89)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 90 to &le; 110</p></td><td style="vertical-align:top"><p>927</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>0.23</p></td><td style="vertical-align:top"><p>960</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>0.26</p></td><td style="vertical-align:top"><p>0.87 (0.27,</p><p>2.86)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 110 to &le; 130</p></td><td style="vertical-align:top"><p>497</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>0.17</p></td><td style="vertical-align:top"><p>469</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>0.26</p></td><td style="vertical-align:top"><p>--<sup>*</sup></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 130</p></td><td style="vertical-align:top"><p>462</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0.09</p></td><td style="vertical-align:top"><p>418</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0.10</p></td><td style="vertical-align:top"><p>--<sup>*</sup></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Abbreviations: N = number of subjects; mITT population overall study period; n = number of patients in subgroup</p><p>&nbsp;</p><p>*HR not computed if number of events &lt; 5 in one treatment group.</p><p>&nbsp;</p><p><sup>a</sup> On-Treatment: Time from first dose of study drug to last dose plus 3 days.</p><p>&nbsp;</p><p>In subgroup analyses, for subjects in the 60 mg treatment group who were dose reduced to 30 mg in the ENGAGE AF-TIMI 48 study for body weight &le; 60 kg, moderate renal impairment, or concomitant use of P-gp inhibitors, 104 (3.05% per year) of edoxaban 30 mg dose reduced subjects and 166 (4.85% per year) of warfarin dose reduced subjects had a major bleeding event [HR (95% CI): 0.63 (0.50, 0.81)].</p><p>&nbsp;</p><p>In the ENGAGE AF-TIMI 48 study there was a significant improvement in Net Clinical Outcome (First Stroke, SEE, Major Bleed, or All-Cause Mortality; mITT population, overall study period) in favour of edoxaban, HR (95% CI): 0.89 (0.83, 0.96); p = 0.0024, when edoxaban 60 mg treatment group was compared to warfarin.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Treatment of DVT, treatment of PE and the prevention of recurrent DVT and PE (VTE)</em></p><p><em>&nbsp;</em></p><p>The edoxaban clinical programme for VTE was designed to demonstrate the efficacy and safety of edoxaban in the treatment of DVT and PE, and the prevention of recurrent DVT and PE.</p><p>&nbsp;</p><p>In the pivotal Hokusai-VTE study, 8,292 subjects were randomised to receive initial heparin therapy (enoxaparin or unfractionated heparin) followed by edoxaban 60 mg once daily or the comparator. In the comparator arm, subjects received initial heparin therapy concurrently with warfarin, titrated to a target INR of</p><p>2.0 to 3.0, followed by warfarin alone. The treatment duration was from 3 months up to 12 months, determined by the investigator based on the patient&#39;s clinical features.</p><p>&nbsp;</p><p>The majority of edoxaban treated patients were Caucasians (69.6%) and Asians (21.0%), 3.8% were Black, 5.3% were categorised as Other race.</p><p>&nbsp;</p><p>The duration of therapy was at least 3 months for 3,718 (91.6%) edoxaban subjects versus 3,727 (91.4%) of warfarin subjects; at least 6 months for 3,495 (86.1%) of edoxaban subjects versus 3,491 (85.6%) of warfarin subjects; and 12 months for 1,643 (40.5%) edoxaban subjects versus 1,659 (40.4%) of warfarin subjects.</p><p>&nbsp;</p><p>The primary efficacy endpoint was the recurrence of symptomatic VTE, defined as the composite of recurrent symptomatic DVT, non-fatal symptomatic PE and fatal PE in subjects during the 12-month study period.</p><p>Secondary efficacy outcomes included the composite clinical outcome of recurrent VTE and all-cause mortality.</p><p>&nbsp;</p><p>Edoxaban 30 mg once daily was used for subjects with one or more of the following clinical factors: moderate renal impairment (CrCL 30 - 50 mL/min); body weight &le; 60 kg; concomitant use of specific P-gp inhibitors.</p><p>&nbsp;</p><p>In the Hokusai-VTE study (Table 10) edoxaban was demonstrated to be non-inferior to warfarin for the primary efficacy outcome, recurrent VTE, which occurred in 130 of 4,118 subjects (3.2%) in the edoxaban group versus 146 of 4,122 subjects (3.5%) in the warfarin group [HR (95% CI): 0.89 (0.70, 1.13); p &lt; 0.0001 for non- inferiority]. In the warfarin group, the median TTR (time in therapeutic range, INR 2.0 to 3.0) was 65.6%. For subjects presenting with PE (with or without DVT), 47 (2.8%) of edoxaban and 65 (3.9%) of warfarin subjects had a recurrent VTE [HR (95% CI): 0.73 (0.50, 1.06)].</p><p>&nbsp;</p><p>Table 10: Efficacy Results from the Hokusai-VTE Study - mITT population, overall study period</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Primary endpoint</strong><strong>a</strong></p></td><td style="vertical-align:top"><p><strong>Edoxaban 60 mg</strong></p><p><strong>&nbsp;</strong></p><p><strong>(30</strong><strong> </strong><strong>mg</strong><strong> </strong><strong>Dose</strong><strong> </strong><strong>Reduced)</strong></p><p><strong>&nbsp;</strong></p><p><strong>(N = 4,118)</strong></p></td><td style="vertical-align:top"><p><strong>Warfarin (N = 4,122)</strong></p></td><td style="vertical-align:top"><p><strong>Edoxaban vs Warfarin</strong></p><p><strong>&nbsp;</strong></p><p><strong>HR (95% CI)</strong><strong>b</strong></p><p><strong>&nbsp;</strong></p><p><strong>p-value</strong><strong>c</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>All subjects with symptomatic recurrent VTE<strong>c</strong>, n (%)</p></td><td rowspan="2" style="vertical-align:top"><p>130 (3.2)</p></td><td rowspan="2" style="vertical-align:top"><p>146 (3.5)</p></td><td style="vertical-align:top"><p>0.89 (0.70, 1.13)</p><p><strong>&nbsp;</strong></p><p>p-value &lt; 0.0001</p></td></tr><tr><td style="vertical-align:top"><p>(non-inferiority)</p></td></tr><tr><td style="vertical-align:top"><p>PE with or without DVT</p></td><td style="vertical-align:top"><p>73 (1.8)</p></td><td style="vertical-align:top"><p>83 (2.0)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fatal PE or Death where PE cannot be ruled out</p></td><td style="vertical-align:top"><p>24 (0.6)</p></td><td style="vertical-align:top"><p>24 (0.6)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Non-fatal PE</p></td><td style="vertical-align:top"><p>49 (1.2)</p></td><td style="vertical-align:top"><p>59 (1.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>DVT only</p></td><td style="vertical-align:top"><p>57 (1.4)</p></td><td style="vertical-align:top"><p>63 (1.5)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Abbreviations: CI = Confidence Interval; DVT = deep vein thrombosis; mITT = modified intent-to-treat; HR = Hazard Ratio vs. warfarin; n = number of subjects with events; N = number of subjects in mITT population; PE</p><p>= pulmonary embolism; VTE = venous thromboembolic events.</p><p>&nbsp;</p><p><sup>a</sup> The primary efficacy endpoint is adjudicated symptomatic recurrent VTE (i.e., the composite endpoint of DVT, non-fatal PE, and fatal PE).</p><p>&nbsp;</p><p><sup>b</sup> The HR, two-sided CI are based on the Cox proportional hazards regression model including treatment and the following randomisation stratification factors as covariates: presenting diagnosis (PE with or without DVT, DVT only), baseline risk factors (temporary factors, all others), and the need for 30 mg edoxaban/edoxaban placebo dose at randomisation (yes/no).</p><p>&nbsp;</p><p><sup>c</sup> The p-value is for the pre-defined non-inferiority margin of 1.5.</p><p>&nbsp;</p><p>For the subjects who were dose reduced to 30 mg (predominantly low body weight or renal function) 15 (2.1%) edoxaban and 22 (3.1%) of warfarin subjects had a recurrent VTE [HR (95% CI): 0.69 (0.36, 1.34)].</p><p>&nbsp;</p><p>The secondary composite endpoint of recurrent VTE and all-cause mortality occurred in 138 subjects (3.4%) in the edoxaban group and 158 subjects (3.9%) in the warfarin group [HR (95% CI): 0.87 (0.70, 1.10)].</p><p>&nbsp;</p><p>The results for all-cause mortality (adjudicated deaths) in Hokusai-VTE were 136 (3.3%) for subjects taking edoxaban 60 mg (30 mg dose reduced) as opposed to 130 (3.2%) for warfarin.</p><p>&nbsp;</p><p>In a pre-specified subgroup analysis of PE subjects 447 (30.6%) and 483 (32.2%) of edoxaban and warfarin treated subjects, respectively, were identified as having PE and NT-proBNP &ge; 500 pg/mL. The primary efficacy outcome occurred in 14 (3.1%) and 30 (6.2%) of edoxaban and warfarin subjects, respectively [HR (95% CI): 0.50 (0.26, 0.94)].</p><p>&nbsp;</p><p>The efficacy results for pre-specified major subgroups (with dose reduction as required), including age, body weight, gender and status of renal function were consistent with the primary efficacy results for the overall population studied in the trial.</p><p>&nbsp;</p><p><em><u>Safety in patients with VTE (DVT and PE) in Hokusai-VTE</u></em></p><p><em>&nbsp;</em></p><p>The primary safety endpoint was clinically relevant bleeding (major or clinically relevant non-major). Table 11 summarises adjudicated bleeding events for the safety analysis set on-treatment period.</p><p>There was a significant risk reduction in favour of edoxaban compared with warfarin for the primary safety endpoint of clinically relevant bleeding, a composite of major bleeding or clinically relevant non-major bleeding (CRNM), which occurred in 349 of 4,118 subjects (8.5%) in the edoxaban group and in 423 of 4,122 subjects (10.3%) in the warfarin group [HR (95% CI): 0.81 (0.71, 0.94); p = 0.004 for superiority].</p><p>&nbsp;</p><p>Table 11: Bleeding Events in Hokusai-VTE Study - Safety Analysis On-Treatment Perioda</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Edoxaban 60 mg</strong></p><p><strong>(30 mg Dose Reduced) (N = 4,118)</strong></p></td><td style="vertical-align:top"><p><strong>Warfarin (N = 4,122)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Clinically Relevant Bleeding</strong></p><p><strong>&nbsp;</strong></p><p>(Major and CRNM)<strong>b</strong>, n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>349 (8.5)</p></td><td style="vertical-align:top"><p>423 (10.3)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)</p></td><td style="vertical-align:top"><p>0.81 (0.71, 0.94)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td style="vertical-align:top"><p>0.004 (for superiority)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Major Bleeding </strong>n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>56 (1.4)</p></td><td style="vertical-align:top"><p>66 (1.6)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)</p></td><td style="vertical-align:top"><p>0.84 (0.59, 1.21)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ICH fatal</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>6 (0.1)</p></td></tr><tr><td style="vertical-align:top"><p>ICH non-fatal</p></td><td style="vertical-align:top"><p>5 (0.1)</p></td><td style="vertical-align:top"><p>12 (0.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>CRNM Bleeding</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>298 (7.2)</p></td><td style="vertical-align:top"><p>368 (8.9)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)</p></td><td style="vertical-align:top"><p>0.80 (0.68, 0.93)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>All Bleeding</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>895 (21.7)</p></td><td style="vertical-align:top"><p>1,056 (25.6)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)</p></td><td style="vertical-align:top"><p>0.82 (0.75, 0.90)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Abbreviations: ICH = Intracranial Haemorrhage, HR = Hazard Ratio vs. warfarin; CI = Confidence Interval; N</p><p>= number of subjects in safety population; n = number of events; CRNM = clinically relevant non-major</p><p>&nbsp;</p><p><sup>a</sup> On-Treatment Period: Time from first dose of study drug to last dose plus 3 days.</p><p>&nbsp;</p><p><sup>b</sup> Primary Safety Endpoint: Clinically relevant bleeding (composite of major and clinically relevant non-major bleeding).</p><p>&nbsp;</p><p>In subgroup analyses, for subjects who were dose reduced to 30 mg in the Hokusai-VTE study for body weight</p><p>&le; 60 kg, moderate renal impairment, or concomitant use of P-gp inhibitors, 58 (7.9%) of edoxaban 30 mg dose reduced subjects and 92 (12.8%) of warfarin subjects had a major bleeding or CRNM event [HR (95%): 0.62 (0.44, 0.86)].</p><p>&nbsp;</p><p>In the Hokusai-VTE study the Net Clinical Outcome (Recurrent VTE, Major Bleed, or All-Cause Mortality; mITT population, overall study period) HR (95% CI) was 1.00 (0.85, 1.18) when edoxaban was compared to warfarin.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with edoxaban in one or more subsets of the paediatric population in prevention of arterial thrombosis, treatment of thromboembolism and prevention of thromboembolism (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>Edoxaban is absorbed with peak plasma concentrations within 1 - 2 hours. The absolute bioavailability is approximately 62%. Food increases peak exposure to a varying extent, but has minimal effect on total exposure. Edoxaban was administered with or without food in the ENGAGE AF-TIMI 48 and the Hokusai-VTE studies. Edoxaban is poorly soluble at pH of 6.0 or higher. Co-administration of proton-pump inhibitors had no relevant impact on edoxaban exposure.</p><p>In a study with 30 healthy subjects, both mean AUC and Cmax values for 60 mg edoxaban administered as a crushed tablet orally mixed in apple puree or via nasogastric tube suspended in water were bioequivalent to the intact tablet. Given the predictable, dose-proportional pharmacokinetic profile of edoxaban, the bioavailability results from this study are likely applicable to lower edoxaban doses.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>Disposition is biphasic. The volume of distribution is 107 (19.9) L mean (SD).</p><p>&nbsp;</p><p><em>In vitro </em>plasma protein binding is approximately 55%. There is no clinically relevant accumulation of edoxaban (accumulation ratio 1.14) with once daily dosing. Steady state concentrations are achieved within 3 days.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Unchanged edoxaban is the predominant form in plasma. Edoxaban is metabolised via hydrolysis (mediated by carboxylesterase 1), conjugation or oxidation by CYP3A4/5 (&lt; 10%). Edoxaban has three active metabolites, the predominant metabolite (M-4), formed by hydrolysis, is active and reaches less than 10% of the exposure of the parent compound in healthy subjects. Exposure to the other metabolites is less than 5%. Edoxaban is a substrate for the efflux transporter P-glycoprotein (P-gp), but not a substrate for uptake transporters such as organic anion transporter polypeptide OATP1B1, organic anion transporters OAT1 or OAT3 or organic cation transporter OCT2. Its active metabolite is a substrate for OATP1B1.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>In healthy subjects, the total clearance is estimated as 22 (&plusmn; 3) L/hour; 50% is renally cleared (11 L/hour). Renal clearance accounts for approximately 35% of the administered dose. Metabolism and biliary/intestinal excretion account for the remaining clearance. The t&frac12; for oral administration is 10 - 14 hours.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>&nbsp;</p><p>Edoxaban displays approximately dose-proportional pharmacokinetics for doses of 15 mg to 60 mg in healthy subjects.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly patients</em></p><p><em>&nbsp;</em></p><p>After taking renal function and body weight into account, age had no additional clinically significant effect on edoxaban pharmacokinetics in a population pharmacokinetic analysis of the pivotal Phase 3 study in NVAF (ENGAGE AF-TIMI 48).</p><p>&nbsp;</p><p><em>Gender</em></p><p><em>&nbsp;</em></p><p>After accounting for body weight, gender had no additional clinically significant effect on edoxaban pharmacokinetics in a population pharmacokinetic analysis of the Phase 3 study in NVAF (ENGAGE AF-TIMI 48).</p><p>&nbsp;</p><p><em>Ethnic origin</em></p><p><em>&nbsp;</em></p><p>In a population pharmacokinetic analysis of the ENGAGE AF-TIMI 48 study, peak and total exposure in Asian patients and non-Asian patients were comparable.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p><em>&nbsp;</em></p><p>The plasma AUCs for subjects with mild (CrCL &gt; 50 - 80 mL/min), moderate (CrCL 30 - 50 mL/min) and severe (CrCL &lt; 30 mL/min but not undergoing dialysis) renal impairment were increased by 32%, 74%, and 72%, respectively, relative to subjects with normal renal function. In patients with renal impairment the metabolite profile changes and a higher quantity of active metabolites are formed.</p><p>&nbsp;</p><p>There is a linear correlation between edoxaban plasma concentration and anti-FXa activity regardless of renal function.</p><p>&nbsp;</p><p>Subjects with ESRD undergoing peritoneal dialysis had 93% higher total exposure compared with healthy subjects.</p><p>&nbsp;</p><p>Population PK modeling indicates that exposure approximately doubles in patients with severe renal impairment (CrCL 15 &ndash; 29 mL/min) relative to patients with normal renal function.</p><p>&nbsp;</p><p><em>Anti-FXa activity by CrCL category</em>Table 12 below shows the edoxaban anti-Factor Xa activity by CrCL category for each indication.</p><p>&nbsp;</p><p>Table 12: Edoxaban Anti-FXa activity by creatinine clearance</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Edoxaban</strong></p></td><td style="vertical-align:top"><p><strong>CrCL</strong></p></td><td style="vertical-align:top"><p><strong>Edoxaban</strong></p></td><td style="vertical-align:top"><p><strong>Edoxaban</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>(mL/min)</strong></p></td><td style="vertical-align:top"><p><strong>Anti-FXa activity</strong></p><p><strong>&nbsp;</strong></p><p><strong>post-dose (IU/mL)</strong><strong>1</strong></p></td><td style="vertical-align:top"><p><strong>Anti-FXa activity</strong></p><p><strong>&nbsp;</strong></p><p><strong>pre-dose (IU/mL)</strong><strong>2</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>Median [2.5 &ndash; 97.5% range]</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Prevention of stroke and systemic embolism: NVAF</p></td></tr><tr><td style="vertical-align:top"><p>30 mg QD</p></td><td style="vertical-align:top"><p>&ge; 30 to &le; 50</p></td><td style="vertical-align:top"><p>2.92</p><p><strong>&nbsp;</strong></p><p>[0.33 &ndash; 5.88]</p></td><td style="vertical-align:top"><p>0.53</p><p><strong>&nbsp;</strong></p><p>[0.11 &ndash; 2.06]</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>60 mg QD<sup>*</sup></p></td><td style="vertical-align:top"><p>&gt; 50 to &le; 70</p></td><td style="vertical-align:top"><p>4.52</p><p><strong>&nbsp;</strong></p><p>[0.38 &ndash; 7.64]</p></td><td style="vertical-align:top"><p>0.83</p><p><strong>&nbsp;</strong></p><p>[0.16 &ndash; 2.61]</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 70 to &le; 90</p></td><td style="vertical-align:top"><p>4.12</p><p><strong>&nbsp;</strong></p><p>[0.19 &ndash; 7.55]</p></td><td style="vertical-align:top"><p>0.68</p><p><strong>&nbsp;</strong></p><p>[0.05 &ndash; 2.33]</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 90 to &le; 110</p></td><td style="vertical-align:top"><p>3.82</p><p><strong>&nbsp;</strong></p><p>[0.36 &ndash; 7.39]</p></td><td style="vertical-align:top"><p>0.60</p><p><strong>&nbsp;</strong></p><p>[0.14 &ndash; 3.57]</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 110 to &le; 130</p></td><td style="vertical-align:top"><p>3.16</p><p><strong>&nbsp;</strong></p><p>[0.28 &ndash; 6.71]</p></td><td style="vertical-align:top"><p>0.41</p><p><strong>&nbsp;</strong></p><p>[0.15 &ndash; 1.51]</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 130</p></td><td style="vertical-align:top"><p>2.76</p><p><strong>&nbsp;</strong></p><p>[0.12 &ndash; 6.10]</p></td><td style="vertical-align:top"><p>0.45</p><p><strong>&nbsp;</strong></p><p>[0.00 &ndash; 3.10]</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTE)</p></td></tr><tr><td style="vertical-align:top"><p>30 mg QD</p></td><td style="vertical-align:top"><p>&ge; 30 to &le; 50</p></td><td style="vertical-align:top"><p>2.21</p><p><strong>&nbsp;</strong></p><p>[0.14 &ndash; 4.47]</p></td><td style="vertical-align:top"><p>0.22</p><p><strong>&nbsp;</strong></p><p>[0.00 &ndash; 1.09]</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>60 mg QD<sup>*</sup></p></td><td style="vertical-align:top"><p>&gt; 50 to &le; 70</p></td><td style="vertical-align:top"><p>3.42</p><p><strong>&nbsp;</strong></p><p>[0.19 &ndash; 6.13]</p></td><td style="vertical-align:top"><p>0.34</p><p><strong>&nbsp;</strong></p><p>[0.00 &ndash; 3.10]</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 70 to &le; 90</p></td><td style="vertical-align:top"><p>2.97</p><p><strong>&nbsp;</strong></p><p>[0.24 &ndash; 5.82]</p></td><td style="vertical-align:top"><p>0.24</p><p><strong>&nbsp;</strong></p><p>[0.00 &ndash; 1.77]</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 90 to &le; 110</p></td><td style="vertical-align:top"><p>2.82</p><p><strong>&nbsp;</strong></p><p>[0.14 &ndash; 5.31]</p></td><td style="vertical-align:top"><p>0.20</p><p><strong>&nbsp;</strong></p><p>[0.00 &ndash; 2.52]</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 110 to &le; 130</p></td><td style="vertical-align:top"><p>2.64</p><p><strong>&nbsp;</strong></p><p>[0.13 &ndash; 5.57]</p></td><td style="vertical-align:top"><p>0.17</p><p><strong>&nbsp;</strong></p><p>[0.00 &ndash; 1.86]</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 130</p></td><td style="vertical-align:top"><p>2.39</p><p><strong>&nbsp;</strong></p><p>[0.10 &ndash; 4.92]</p></td><td style="vertical-align:top"><p>0.13</p><p><strong>&nbsp;</strong></p><p>[0.00 &ndash; 2.43]</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><sup>*</sup>Dose reduction to 30 mg for low body weight &le; 60 kg or specific concomitant P-glycoprotein (P-gp) inhibitors</p><p>&nbsp;</p><p><sup>1</sup> Post-dose&nbsp;is&nbsp;equivalent to Cmax (post-dose&nbsp;samples&nbsp;were drawn 1 &ndash; 3 hours after edoxaban administration)</p><p>&nbsp;</p><p><sup>2</sup> Pre-dose&nbsp;is&nbsp;equivalent to Cmin</p><p>&nbsp;</p><p>Although treatment with edoxaban does not require routine monitoring, the effect on anticoagulation can be estimated by a calibrated quantitative anti-Factor Xa assay which may be useful in exceptional situations where knowledge of edoxaban exposure may help to inform clinical decisions, e.g. overdose and emergency surgery (see also section 4.4).</p><p>&nbsp;</p><p><em>Haemodialysis</em></p><p><em>&nbsp;</em></p><p>A 4 hour haemodialysis session reduced total edoxaban exposures by less than 9%.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p><em>&nbsp;</em></p><p>Patients with mild or moderate hepatic impairment exhibited comparable pharmacokinetics and pharmacodynamics to their matched healthy control group. Edoxaban has not been studied in patients with severe hepatic impairment (see section 4.2).</p><p>&nbsp;</p><p><em>Body weight</em></p><p><em>&nbsp;</em></p><p>In a population pharmacokinetic analysis of the ENGAGE AF-TIMI 48 study in NVAF, Cmax and AUC in patients with median low body weight (55 kg) were increased by 40% and 13%, respectively, as compared with patients with median high body weight (84 kg). In Phase 3 clinical studies (both NVAF and VTE indications) patients with body weight &le; 60 kg had a 50% edoxaban dose reduction and had similar efficacy and less bleeding when compared to warfarin.</p><p>&nbsp;</p><p><u>Pharmocokinetic/pharmacodynamic relationship(s)</u></p><p>&nbsp;</p><p>PT, INR, aPTT and Anti-factor Xa correlate linearly with edoxaban concentrations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, or phototoxicity.</p><p>&nbsp;</p><p><em>Reproductive toxicology</em></p><p><em>&nbsp;</em></p><p>Edoxaban showed vaginal haemorrhage at higher doses in rats and rabbits but had no effects in the reproductive performance of parent rats.</p><p>&nbsp;</p><p>In rats, no effects on male or female fertility were seen.</p><p>&nbsp;</p><p>In animal reproduction studies, rabbits showed increased incidence of gallbladder variations at a dosage of 200 mg/kg which is approximately 65 times the maximum recommended human dose (MRHD) of 60 mg/day based on total body surface area in mg/m<sup>2</sup>. Increased post-implantation pregnancy losses occurred in rats at 300 mg/kg/day (approximately 49 times the MRHD) and in rabbits at 200 mg/kg/day (approximately 65 times the MRHD) respectively.</p><p>&nbsp;</p><p>Edoxaban was excreted in the breast milk of lactating rats. <u>Environmental Risk Assessment (ERA)</u></p><p>&nbsp;</p><p>The active substance edoxaban tosilate is persistent in the environment (for instructions on disposal see section 6.6).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core: </u></p><p>Mannitol (E421) Pregelatinised starch Crospovidone Hydroxypropylcellulose Magnesium stearate (E470b)</p><p>&nbsp;</p><p><u>Film-coat: </u></p><p>Hypromellose (E464) Macrogol 8000 Titanium dioxide (E171) Talc</p><p>Carnauba wax</p><p>Iron oxide red (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>This medicinal product does not require any special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC-PVDC/Aluminum blisters. Cartons of 28 film-coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SAJA Pharmaceuticals

Under license from Daiichi Sankyo company limited.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>